

Ketamine—Its Pharmacology and Therapeutic Uses

Paul F. White, Ph.D., M.D.,* Walter L. Way, M.D.,† Anthony J. Trevor, Ph.D.†

CONTENTS

Introduction

Basic Pharmacology

Central nervous system effects

Post-anesthesia emergence reactions

Cardiovascular effects

Pulmonary effects

Miscellaneous pharmacologic effects

Biodisposition, pharmacokinetics, and drug interactions

Optical isomers of ketamine

Clinical Applications

Burn patients

Aged and critically ill patients

Obstetrical anesthesia

Outpatient anesthesia

Adjunct to local and regional anesthesia

Cardiothoracic anesthesia

Conclusions

AN INCREASING INTEREST in intravenous anesthetic techniques has resulted from the availability of more efficacious intravenous agents, the rising cost of traditional volatile agents, and concern over anesthetic gas pollution in the operating room. Although the "ideal" intravenous anesthetic agent is yet to be developed, such an agent might possess the physical and pharmacological properties outlined in table 1. Originally, interest in such an intravenous anesthetic prompted the investigation of phencyclidine (CI-395, PCP, or Sernyl®) and its congener (CI-400, cyclohexamine). These drugs produced an adequate anesthetic state but long-lasting psychotomimetic activity during the postanesthetic period precluded their widespread clinical use.¹⁻³ Further research led to the clinical evaluation of ketamine (CI-581, Ketalar® or Ketaject®) which provided adequate surgical

anesthesia, a rapid recovery and less prominent emergence reactions.⁴ The ketamine molecule [2-(O-chlorophenyl)-2-methylamino cyclohexanone], which structurally resembles phencyclidine and cyclohexamine, has a molecular weight of 238, is water soluble, has a pK_a of 7.5,⁵ and contains a chiral center producing two resolvable optical isomers or enantiomers (fig. 1). Although the racemic mixture (containing equal amounts of the two ketamine isomers) was approved for general clinical use in 1970, its clinical usefulness has been limited because of its cardiovascular-stimulating properties and high incidence of disturbing emergence reactions. In this review the authors will discuss the basic pharmacology of ketamine and its optical isomers and evaluate current clinical applications of this unique sedative, analgesic, and anesthetic drug.

Basic Pharmacology

CENTRAL NERVOUS SYSTEM (CNS) EFFECTS

Ketamine produces a so-called "dissociative" anesthetic state which has been described as a functional and electrophysiological dissociation between the thalamo-neocortical and limbic systems.⁶ The unique clinical anesthetic state produced by ketamine has been characterized as a state of catalepsy in which the eyes remain open with a slow nystagmic gaze while corneal and light reflexes remain intact. Varying degrees of hypertonus and occasional purposeful movements unrelated to painful stimuli are noted in the presence of adequate surgical anesthesia. Judging the adequacy of anesthesia consists primarily of noting the presence or absence of purposeful responses to noxious stimuli. Minor CNS changes occur even after subanesthetic doses of ketamine.⁷ These changes may interfere with one's ability to organize thoughts and understand the environment during emergence.

Early EEG studies by Domino *et al.*⁴ reported depression of thalamo-neocortical pathways (producing hypersynchronous delta waves) and concomitant activation of the limbic system. Subsequent studies⁸ have demonstrated excitatory activity in both the thalamus and limbic systems without clinical evidence of seizure activity following the administration of ketamine. Thus, although thalamic and limbic epileptiform patterns exist, there is no evidence that this seizure activity spreads to cortical

* Assistant Professor, Department of Anesthesia, Stanford University Medical Center, Stanford, California 94305.

† Professor, Departments of Anesthesia and Pharmacology, University of California, San Francisco, California 94143.

Received from the Department of Anesthesia, Stanford University Medical Center, Stanford, California 94305, and the Departments of Anesthesia and Pharmacology, University of California, San Francisco, California 94143. Accepted for publication August 6, 1981.

Address reprint requests to Dr. White: Stanford University Medical Center, Department of Anesthesia, Room S268, Stanford, California 94305.

TABLE 1. Physical and Pharmacological Properties of an Ideal Intravenous Anesthetic

1) Water-soluble, stable in solution, and long shelf-life
2) Nonirritating following im or iv administration
3) No hypersensitivity reactions
4) Rapid, smooth onset of action following im or iv administration
5) Minimal depression of cardiovascular and respiratory systems
6) Rapid degradation to inactive, nontoxic metabolites
7) Analgesia at subanesthetic levels
8) Rapid, smooth emergence (short elimination half-life) with minimal side-effects

areas.^{9,10} In fact, Celesia *et al.*¹¹ found that natural sleep was a more potent stimulator of convulsions than ketamine in the epileptic patient. Thus, ketamine would be an unlikely agent to precipitate generalized convulsions in patients with seizure disorders and in fact, recent experimental data suggest that ketamine has anticonvulsant properties.¹²

Early observations suggested that analgesia following ketamine administration outlasted the period of anesthesia^{13,14} and that this analgesic effect occurred even at subanesthetic doses of ketamine.¹⁵⁻¹⁷ A number of experimental observations suggest explanations for its analgesic action. Massopust *et al.*¹⁸ showed that ketamine produces a selective depressant effect on the medial thalamic nuclei. This observation was supported by the work of Sparks and colleagues,^{19,20} who demonstrated that ketamine blocks afferent signals associated with the affective-emotional components of pain perception (*e.g.*, the spinoreticular tracts) without significantly impairing conduction of signals related to localization of somatic stimuli (*e.g.*, the spinothalamic tracts). Ohtani *et al.*²¹ demonstrated a highly selective depression of nuclei involved in the transmission of impulses within the medial medullary reticular formation, a presumed relay station for the transmission of the affective-emotional components of nociception from the spinal cord to higher brain centers. Others²²⁻²⁴ suggest that the analgesic action of ketamine may be explained in part by lamina-specific suppression of spinal cord activity. There is also evidence to suggest that ketamine binds stereospecifically to opiate receptors,²⁵⁻²⁷ possibly competing with narcotic analgesics and endogenous morphine-like compounds for CNS and spinal cord receptor sites. However, other investigators have been unable to find evidence for an interaction between ketamine and opiate receptors.²⁸

Ketamine affects CNS neurotransmitter systems, including interactions with cholinergic receptors of the muscarinic type²⁵ and brain acetylcholinesterase.²⁹ Acetylcholine turnover rates were found to be reduced in the rat caudate nucleus and hippocampus during ketamine anesthesia,³⁰ suggesting that acetylcholine utilization may be related to ketamine-induced electrophysiologic changes in these subcortical structures. The clinical relevance of

such experimental observations to analgesia or other neuropharmacological effects of ketamine awaits further clarification. However, several investigators have reported that the centrally-active anticholinesterase physostigmine antagonizes the sedative and anesthetic actions of ketamine while not affecting its analgesic properties.³¹⁻³³ Others have found that physostigmine is unable to reverse the CNS effects produced with anesthetic doses of ketamine.³⁴ Interestingly, Agoston *et al.*³⁵ recently reported that 4-aminopyridine, a potent antagonist of non-depolarizing myoneural blocking drugs, enhanced the rate of recovery from ketamine-diazepam anesthesia.

POSTANESTHESIA EMERGENCE REACTIONS

The psychic sensations reported during emergence from ketamine anesthesia have been characterized as alterations in mood state and body image, dissociative or extracorporeal (out-of-body) experiences, floating sensations, vivid dreams or illusions, "weird trips," and occasional frank delirium.³⁶ The vivid dreams and visual illusions usually disappear immediately upon waking, although recurrent illusions (flashbacks) have been reported several weeks after ketamine administration in adults³⁷ and children.^{38,39}

Recent cerebral glucose utilization studies in animals indicate that ketamine produces depressive action on the inferior colliculus (a primary acoustic relay nucleus) and the medial geniculate (a visual relay nucleus).^{40,41} It would appear that psychic emergence reactions occur secondary to ketamine-induced depression of these auditory and visual relay nuclei, leading to misperception and/or misinterpretation of auditory and visual stimuli. Furthermore, the loss of skin and musculoskeletal sensations results in a decreased ability to feel gravity, thereby producing a sensation of bodily detachment or floating in space.⁴² Despite many statements in the literature to the contrary, there is no evidence that covering the eyes during the operative and postoperative periods or allowing patients to emerge in a quiet area alters the incidence of emergence reactions.⁴³ In fact, we would emphasize the importance of both preoperative and postoperative discussions with the patient regarding the expected effects of ketamine and its common side-effects (*e.g.*, vivid dreaming, floating sensations, dizziness, and




FIG. 1. Absolute configuration of ketamine isomers.

blurred vision). In our experience this has reduced the incidence of unpleasant emergence sequelae irrespective of the adjunctive agent used.

The psychic disturbances following ketamine vary in incidence from less than 5 per cent^{44,45} to greater than 30 per cent.^{36,46-48} Various factors associated with a higher incidence of emergence reactions include: age (less than 10 per cent incidence of unsatisfactory anesthesia and/or emergence reactions in patients less than 16 years old *vs.* 24-34 per cent in patients greater than 16 years old);⁴⁹ sex (females greater than males); subjects who normally dream; large doses of ketamine (>2 mg/kg, iv); rapid iv administration (>40 mg/min);^{43,50-52} or a history of personality problems.⁵³ In a controlled study, Garfield *et al.*⁵⁴ concluded that ketamine has the property of producing auditory, visual, proprioceptive and confusional illusions in common with other general anesthetics; however, the incidence was significantly higher with ketamine. When compared to a general anesthetic regimen including thiopental, nitrous oxide and halothane, the degree of postoperative anxiety was found to be no greater in patients who only received ketamine.⁵⁴ A comparison of the psychological changes in children after either ketamine or halothane/nitrous oxide anesthesia revealed no significant differences.⁵⁵

A variety of premedicants and adjunctive agents have been evaluated in attempts to prevent the untoward emergence reactions following ketamine anesthesia. Atropine premedication prior to ketamine administration has been shown to increase the frequency of unpleasant dreams.^{50,56} Similarly, droperidol may increase the occurrence of vivid dreams when used as a premedicant,^{46,50,57,58} although it was originally reported to reduce the incidence of adverse emergence reactions.⁵⁹ Furthermore, even though droperidol may reduce the total dosage of ketamine, patients receiving droperidol tended to be significantly less alert, less responsive, and more disoriented during the recovery period.⁶⁰ Several investigators have reported a decrease in the incidence of posthypnotic emergence phenomenon when ketamine was used in conjunction with sedative-hypnotics (*e.g.*, thiopental)⁶¹ or other general anesthetics (*e.g.*, halothane, enflurane and nitrous oxide).^{62,63}

Benzodiazepines appear to be the most efficacious in attenuating the psychic actions of ketamine during the emergence period. Diazepam (0.15-0.3 mg/kg, iv) has been reported to significantly decrease the incidence of dreams and to eliminate postoperative illusions when administered prior to induction of ketamine anesthesia.^{64,65} In terms of its ability to attenuate emergence sequelae, others have reported diazepam to be equally effective whether administered at the outset or at the completion of the procedure.^{46,66} Although diazepam is highly effective in preventing vivid emergence reactions

and delirium following ketamine, a high incidence of floating sensations, dizziness and dreaming has been reported even in the presence of diazepam.⁶⁷

Of the currently available benzodiazepines, lorazepam (2-4 mg, po or iv) is reported to be the most effective in preventing unpleasant dreams and emergence sequelae after ketamine.^{68,69} The enhanced effectiveness of lorazepam may be related to its ability to produce more effective and longer-lasting amnesia than diazepam.⁷⁰⁻⁷² A more recently introduced benzodiazepine, flunitrazepam, 0.03 mg/kg, iv, also attenuates the emergence sequelae associated with ketamine anesthesia.⁷³⁻⁷⁵ Unfortunately all currently available benzodiazepines are insoluble in water and possess long elimination half-life values. Thus, they produce a high incidence of phlebitis and contribute to a prolonged recovery when used as adjuncts to ketamine. A new shorter-acting benzodiazepine, midazolam, appears to offer several potential advantages since this water-soluble agent prevented dreaming and emergence sequelae when used as an adjunct to ketamine for induction of general anesthesia.‡

CARDIOVASCULAR EFFECTS

Ketamine produces a dose-related rise in the rate-pressure product (often in excess of 100 per cent) with a transient rise in the cardiac index but without significantly altering the stroke index.^{76,77} Initially, the cardio-stimulatory effects of ketamine were thought to be due to increased sympathetic nervous system activity, with enhanced norepinephrine release secondary to depression of baroreceptor reflex activity.⁷⁸ Subsequent studies^{79,80} have shown that the cardiovascular stimulation associated with ketamine was not altered by direct baroreceptor nerve stimulation, while ketamine blocked the bradycardia produced by stimulation of the depressor nerve, suggesting that the origin of ketamine-induced cardiovascular stimulation is unrelated to baroreceptor desensitization. Traber *et al.*⁸¹ suggested that the sympathomimetic effects of ketamine might be mediated within the CNS because ganglionic blockade and thoracic epidural block were capable of ablating its cardiostimulatory properties (even though adrenergic-blocking drugs were unable to completely block the pressor response to ketamine). In fact, when ketamine is injected directly into the cerebral circulation, an immediate increase in blood pressure, heart rate, and cardiac output is produced and these effects can be markedly attenuated by prior administration of pentobarbital.⁸² Based on this study and others,^{83,84} it is felt that ketamine produces its sympathomimetic actions *primarily* by direct stimulation of CNS structures.

‡ White PF: Unpublished data.

In the absence of autonomic control, ketamine has direct myocardial depressant properties.^{85,86} *In vitro*, ketamine produced a dose-dependent decrease in the rate and force of myocardial contraction which was not altered by pretreatment with atropine, phentolamine, or propranolol.⁸⁷⁻⁸⁹ Furthermore, the ketamine-induced myocardial depression is antagonized by hypothermia.^{87,90}

The effect of ketamine on the cardiac rhythm is controversial. There is evidence to suggest that ketamine has the ability to sensitize the myocardium to catecholamines and thereby enhance the arrhythmogenicity of epinephrine;^{91,92} however, these same investigators have demonstrated a transient dose-related antiarrhythmic effect of ketamine. In animal studies, ketamine abolished epinephrine-induced arrhythmias by prolonging the relative refractory period^{77,78} and was capable of reversing digitalis-induced arrhythmias.⁹³

The cardiovascular effects of ketamine are not confined to actions on CNS centers and the heart. Several investigators have suggested that ketamine has both inhibitory and excitatory effects on the peripheral sympathetic nervous system.⁹⁴⁻⁹⁵ Juang *et al.*⁹⁶ demonstrated that ketamine depressed smooth muscle contraction in response to preganglionic stimulation, while producing a transiently increased contraction in response to postganglionic stimulation, suggesting an effect at the level of the sympathetic ganglia. The effects of ketamine on postganglionic adrenergic neurons include inhibition of intraneuronal uptake of catecholamines, *i.e.*, a cocaine-like effect^{90,95,97,98} and a dose-dependent inhibition of extraneuronal norepinephrine uptake.^{99,100}

Recent studies have demonstrated that ketamine directly dilates vascular smooth muscle while causing sympathetically mediated vasoconstriction.^{101,102} The net effect is that systemic vascular resistance is not significantly altered by ketamine.^{86,103} Even though ketamine increases coronary blood flow, it may be insufficient to meet the metabolic demands of the myocardium produced by the increase in the rate-pressure product and cardiac work.^{104,105} A recent study¹⁰⁶ found no change in myocardial oxygen extraction with ketamine administration because the increase in coronary blood flow was accompanied by a comparable rise in myocardial oxygen consumption.

Ketamine was found to increase pulmonary artery pressures in dogs.¹⁰⁷ Similarly, in patients, ketamine markedly elevates pulmonary artery pressure and right ventricular stroke work secondary to increased pulmonary vascular resistance.¹⁰⁸ Thus, ketamine is probably contraindicated in patients with minimal right ventricular reserve (*e.g.*, pulmonary emboli and pulmonary hypertension). In patients without cardiopulmonary disease, ketamine produced a 40 per cent increase in pulmonary vascular resistance, a secondary increase in right

heart work, and a transient 20 per cent increase in the intrapulmonary shunt.¹⁰³

In experimental hemorrhagic and septic shock, Wong and Jenkins¹⁰⁹ demonstrated a significant increase in both systolic and diastolic blood pressure after ketamine. Furthermore, while cardiac output was increased in endotoxic shock, it was unchanged in hemorrhagic shock. Longnecker and Sturgill¹¹⁰ reported a higher survival rate in hypotensive rats anesthetized with ketamine than halothane. However, Weiskopf *et al.*¹¹¹ using a graded hemorrhage dog model, found that although continuous ketamine anesthesia was more effective in maintaining the cardiovascular system, it produces a greater base deficit and larger increases in arterial lactate concentration than the volatile anesthetic agents.

Critically ill patients occasionally respond to ketamine with an unexpected drop in blood pressure which may result from the inability of the sympathomimetic actions of ketamine to counterbalance its direct myocardial depressant and vasodilatory effects. Waxman *et al.*¹¹² observed occasional decreases in cardiac and pulmonary performance when ketamine was used for induction of anesthesia in critically ill and acutely traumatized patients. Furthermore, others have demonstrated that general anesthetics block the cardiovascular-stimulating properties of ketamine such that significant cardiovascular depression can be produced when ketamine is used during halothane or enflurane anesthesia.^{62,113}

Using ketamine and thiopental as part of a balanced anesthetic technique decreases the degree of cardiac stimulation produced by ketamine.¹¹⁴ Others have shown that ketamine-induced cardiovascular stimulation and the concomitant rise in plasma free norepinephrine levels may be significantly decreased by premedication with diazepam (0.2–0.5 mg/kg, iv).¹¹⁵⁻¹¹⁷ Although lorazepam is more effective than diazepam in preventing emergence reactions, it is unable to block the cardiovascular stimulation produced by ketamine.¹¹⁸ Of the newer benzodiazepines, flunitrazepam¹¹⁹ and midazolam[§] appear to be the most effective in attenuating the cardiostimulatory properties of ketamine. Nevertheless, the clinical significance of ketamine-induced cardiovascular stimulation in patients without hypertension, coronary artery disease, or cerebral vascular disease is yet to be established.

Ketamine produces an increase in cerebrospinal fluid (CSF) pressure which appears related to an increase in cerebral blood flow secondary to cerebral vasodilation and a rise in systemic blood pressure.^{120,121} Hence, ketamine should probably be avoided in patients with abnormal CSF flow dynamics or other intracranial pathology. Case reports have described ketamine-induced apnea secondary to medullary compression resulting

§ White PF: Unpublished data.

from increased intracranial pressure.^{122,124} The increase in cerebral blood flow produced by ketamine is blunted effectively by prior administration of either thiopental¹²⁵ or diazepam.¹²⁶

PULMONARY EFFECTS

In patients spontaneously breathing room air, ketamine, 2 mg/kg, iv, given as a rapid bolus injection produced significant reductions in PaO_2 lasting from 5–10 minutes.¹²⁷ In contrast, premedicated patients (diazepam 10–15 mg, im) spontaneously breathing room air who received ketamine, 2 mg/kg, iv, over 60 seconds showed no significant change in either PaO_2 or C(a-v)O_2 .¹²⁸ Furthermore, when an infusion of ketamine, 1 mg/kg, iv, was administered during vaginal deliveries, no significant changes were noted in either maternal or infant arterial blood gas values.¹²⁹ The respiratory response to CO_2 challenge is maintained during ketamine anesthesia.¹³⁰ Thus, ketamine does not produce significant respiratory depression except in those situations when it is given as a rapid iv infusion. Furthermore, Lumb *et al.*¹³¹ found consistently lower shunt fractions and higher PaO_2 values when a continuous infusion of ketamine was compared to halothane during one-lung anesthesia in dogs.

In early clinical studies, an increase in pulmonary compliance and a decrease in airway resistance and bronchospasm was noted following administration of ketamine to patients with reactive airway disease.^{132,133} *In vitro* bronchial smooth muscle studies with ketamine demonstrated muscle relaxation, antagonism of the spasmogenic effects of carbachol and histamine, and a potentiation of the antispasmodic effects of epinephrine.^{134,135} Moreover, propranolol blocked the relaxant effect of epinephrine but not that of ketamine, suggesting that *in vitro* ketamine acts at sites other than beta-receptors. Ketamine was found to be as effective as halothane or enflurane in preventing experimentally induced bronchospasm in dogs.¹³⁶ The ability of ketamine to antagonize antigen-induced bronchospasm might be related in part to its vagolytic and direct smooth muscle relaxant effects. However, the major component *in vivo* appears to be related to ketamine's sympathomimetic properties since the protective effect against antigen-induced bronchospasm is lost in the presence of beta-adrenergic blockade.

Salivary and tracheal-bronchial mucus gland secretions are increased by ketamine, necessitating prophylactic administration of an antisialogogue. Despite alleged retention of the protective pharyngeal and laryngeal reflexes,¹³⁷ tracheal soiling and aspiration has been reported following induction of anesthesia with ketamine.^{138,139} Clearly, one should *not* assume that the use of ketamine obviates the need for careful airway management and/or endotracheal intubation in all situations.

MISCELLANEOUS PHARMACOLOGIC EFFECTS

Ketamine frequently produces an increase in skeletal muscle tone⁴ and occasionally muscle spasms,¹⁴⁰ although it has been used safely in patients with myopathies¹⁴¹ and malignant hyperthermia.^{141,142} In the rat phrenic nerve-hemidiaphragm preparation, ketamine has been shown to increase indirectly evoked twitch tension but produced no effect on directly stimulated skeletal muscle.^{143,144} However, a more recent study reported that ketamine produces neuromuscular effects by a direct postsynaptic action, initially potentiating and then blocking the twitch response elicited by direct muscle stimulation.¹⁴⁵ These data suggest that ketamine may interfere with calcium binding or its fluxes and thereby contribute to the initial potentiation and subsequent depression of twitch tension. These actions might explain ketamine's enhancement of the neuromuscular actions of succinylcholine, *d*-tubocurarine, and pancuronium.^{144,146,147}

The reduction in blood loss which has been reported when ketamine is used as an induction agent for first trimester abortions,¹⁴⁸ may be related to its ability to increase both uterine tone as well as the intensity of uterine contractions.^{149,150} In parturients, ketamine has been reported to have variable effects on uterine tone and contractility.^{151–154} Oats *et al.*¹⁵⁵ found that ketamine was able to induce contractions equal to ergometrine, when administered during the first trimester of pregnancy, but exerted no effect in the third trimester. Although ketamine had no effect on basal uterine tone in the parturient, Marx *et al.*¹⁵⁶ reported that ketamine produces dose-related changes in uterine activity in the term pregnant uterus. Analgesic doses of ketamine (0.2–0.4 mg/kg, iv) produced no significant effects, while larger induction doses (>1 mg/kg, iv) produced increases in the intensity of uterine contractions.

Ketamine has reportedly been used safely in a patient with acute intermittent porphyria.¹⁵⁷ Nevertheless, it can increase ALA synthetase activity in animals and therefore should be used with caution in patients with porphyria.¹⁵⁸

Ketamine produces only a mild elevation in blood glucose (12 per cent) compared to that produced by halothane (55 per cent) or thiopental (72 per cent).¹⁵⁹ Serum free fatty acids are decreased by ketamine (13 per cent) in contrast to halothane and thiopental which produce 59 per cent and 34 per cent increases, respectively.¹⁵⁹ Thyroxine (T4) levels are not altered by ketamine; however, T3 levels are reduced.¹⁶⁰ Therefore, the dose-dependent hypothermia produced by ketamine in rats at ambient temperatures¹⁶¹ may be due to decreased heat

¹ Lees, DE, Emma P, Hittner K, et al: The safety of ketamine in pediatric neuromuscular disorders. *Int Anesth Res Soc* 53rd Congress, p 75, 1979.




FIG. 2. Biotransformation of ketamine.

production as well as increased heat loss secondary to cutaneous vasodilation.

Initial studies indicated that ketamine increased plasma renin activity,¹⁶² an effect which was attenuated by prior treatment with antihypertensive agents.¹⁶³ However, recent studies¹⁶⁴ demonstrated no change in renin activity during ketamine anesthesia, even though the pressor response to angiotension I and II was accentuated when compared to that produced under halothane anesthesia. In addition, ketamine produces an activation of the pituitary-adrenal axis,^{165,166} with adrenal release of catecholamines¹⁶⁷ and corticosteroids.¹⁶⁸ During deep ketamine anesthesia inhibition of this pituitary activation was reported,¹⁶⁹ although intense and prolonged stimulation was noted upon emergence.

BIODISPOSITION, PHARMACOKINETICS, AND DRUG INTERACTIONS

Ketamine is metabolized extensively by hepatic drug-metabolizing enzyme systems and although some biotransformation pathways are well-established, others remain postulated. A recently advanced scheme of ketamine metabolism is presented in figure 2.¹⁷⁰ A major pathway of biotransformation involves N-demethylation of ketamine via cytochrome P-450 enzymes to form norketamine (metabolite I) which can then be hydroxylated at one or more positions in the cyclohexanone ring to form hydroxy-norketamine compounds, which in turn can be conjugated to more water-soluble glucuronide derivatives. Ketamine can also undergo ring hydroxylation without prior N-demethylation but quantitatively, this pathway appears to be of minor importance. The hydroxylated metabolites of norketamine are unstable at high temperatures, undergoing thermal dehydration to form a cyclohexenone oxidation product, dehydronorketamine, which has been designated "metabolite II" in much of the past literature on ketamine metabolism. Adams *et al.*¹⁷⁰ have evidence that this compound results artifactually from the gas chromatographic method¹⁷¹

used by most investigators for analysis of ketamine and its metabolites.

Following its intravenous administration, less than 4 per cent of a dose of ketamine can be recovered from urine as either unchanged drug or norketamine and only 16 per cent appears as hydroxylated derivatives.¹⁷² Fecal excretion accounts for less than 5 per cent of an injected dose of ketamine.¹⁷³ The precise composition of the balance of metabolites of ketamine that are eliminated is not clear, but it is presumed that the major components are glucuronide derivatives of the various hydroxylated intermediates.

Only minimal attention has been given to the possible pharmacological effects of the different metabolites of ketamine. In animal studies, norketamine appears to be from one-fifth to one-third as potent as ketamine as an anesthetic,^{174,175} but nothing is known concerning other metabolites. It would be of interest to ascertain if other identified metabolites have either cardiovascular or CNS actions that contribute to adverse effects of the parent drug. Alternatively, certain metabolites could be devoid of such effects while retaining therapeutically useful analgesic or anesthetic properties.

The pattern of biodisposition of ketamine is in some ways analogous to that of the short-acting barbiturates such as thiopental, which it resembles in terms of its rapid onset of action, relatively short duration of hypnotic effects, and its high lipid solubility. Peak plasma levels are achieved within one minute following intravenous administration of ketamine to animals and within five minutes following intramuscular injection.^{176,177} Initially, ketamine is distributed to highly perfused tissues, including the brain, to achieve levels four to five times that of the plasma.^{5,177,178} Subsequently, the drug is redistributed from vessel-rich tissues to less well-perfused tissues.

In experiments to determine relationships between the effects of ketamine and its biodisposition, it was shown that the duration of hypnosis was not affected by either the induction or inhibition of drug-metabolizing enzymes^{5,178} or decreases in renal clearance of the drug.¹⁷⁹ This suggests that redistribution of ketamine from the brain to other tissues is primarily responsible for termination of its hypnotic or anesthetic effects. Hepatic metabolism is important for the ultimate clearance of ketamine from the body and may be a factor in terminating postanesthetic effects of the drug. Pharmacokinetic studies of ketamine in humans, using a two-compartment model system,^{172,180} demonstrate that the initial distribution phase of intravenous ketamine from the central compartment (plasma) to peripheral tissue compartments occurs with a half-life ($t_{1/2}$) of 7 to 11 minutes. The elimination phase, which reflects both metabolic and excretory processes, occurs with a half-life ($t_{1/2}$) of be-

tween 2 and 3 hours. Using a continuous infusion technique, Idvall *et al.*⁷⁷ reported an elimination $t_{1/2}$ of 79 minutes.

At the termination of the ketamine-induced anesthetic state, a large fraction of the ketamine administered remains in body tissues in unchanged form and this may have significance with respect to cumulative effects and the potential for drug interactions. Halothane has been shown to slow distribution and redistribution of ketamine and to inhibit its hepatic metabolism,¹⁷⁷ both actions contributing to a prolongation of the CNS effects of the drug. In animal studies, ketamine caused a dose-dependent decrease in halothane anesthetic requirement, and even at subhypnotic doses ketamine elicited prolonged decreases in halothane MAC.¹⁷⁵ Agents used as adjuvants in anesthesia, including diazepam and secobarbital, have been shown to prolong the elimination half-life of ketamine and to delay recovery from ketamine anesthesia.¹⁸¹ When given intravenously during induction, diazepam caused an increase in ketamine plasma levels and a decrease in its clearance rate,¹⁸⁰ effects which are presumed to reflect inhibition of hepatic metabolism of ketamine by the benzodiazepine. Other premedications have been reported to prolong recovery from the anesthetic effects of ketamine.¹⁸² On the other hand, nitrous oxide has been shown to significantly reduce the dosage of ketamine required for surgical anesthesia and to shorten the recovery period.¹⁸³ It is not clear whether such drug interactions are based on changes in the biodisposition of ketamine or if they reflect pharmacodynamic factors.

The chronic administration of ketamine to laboratory animals results in an increase in activity of hepatic drug-metabolizing enzymes, including those responsible for metabolism of ketamine itself.¹⁷⁸ By increasing the levels of cytochrome P-450, NADPH reductase and the rate of metabolism of Type I substrates, ketamine resembles phenobarbital.¹⁸⁴ The "self-inductive" effects of chronic ketamine administration increases the activity of enzymes involved in its own metabolism and could modify responses to repeated administration of the drug. Such a mechanism could explain, at least in part, the reported occurrence of tolerance to the analgesic effects of ketamine that occur in burn and radiotherapy patients following repeated exposures to the drug.^{17,185-187} Moreover, certain effects of ketamine on animal behavior are subject to rapid "acute" tolerance¹⁸⁸ or to tolerance that develops after only a single prior exposure to the drug.¹⁸⁹ These latter alterations in drug response are unlikely to result from changes in metabolism or biodisposition of the drug. Finally, ketamine maintains self-administration behavior in a manner similar to CNS depressant drugs¹⁹⁰ and not surprisingly, several cases of ketamine abuse have been reported.¹⁹¹⁻¹⁹³

OPTICAL ISOMERS OF KETAMINE

All of the studies of ketamine cited above concern the drug in its racemic form, though a chiral center at C₂ of the cyclohexanone ring permits the existence of two resolvable optical isomers or enantiomers, which when studied by physical chemistry techniques have absolute configurations of S(+)-ketamine hydrochloride and R(-)-ketamine hydrochloride, respectively.** The individual optical isomers of a number of psychoactive compounds, including hallucinogens,¹⁹⁴ amphetamines,¹⁹⁵ narcotics,¹⁹⁶ and sedative-hypnotics¹⁹⁷ are well-established to differ in pharmacological properties. Thus, it is not surprising that the individual ketamine isomers would have the potential for differences in their neuropharmacological effects. In rats, the (+)-enantiomer of ketamine was shown to have a higher therapeutic index, expressed as LD₅₀ over ED₅₀ (hypnosis), than the racemate or (-)-ketamine and at equihypnotic doses the (+)-enantiomer caused less stimulation of locomotor activity than (-)-ketamine.¹⁹⁸ The relative pharmacological properties of the optical isomers of ketamine have also been compared in mice.¹⁹⁹ In these studies, (+)-ketamine was shown to be three times more potent than (-)-ketamine as an analgesic, and 1.5 times more potent in terms of its hypnotic effects. More importantly, at equianalgesic doses the (+)-isomer caused less excitation than (-)-ketamine. Such neuropharmacological differences are quantitative, but recently it has been possible to demonstrate important qualitative differences between the two ketamine isomers. In rats, (-)-ketamine increased the rate of schedule-controlled responding behavior in a dose-dependent manner, while (+)-ketamine did not increase response rate at any dose, acting solely as a depressant of such behavior.²⁰⁰ Observations of this type at the animal level, provided the incentive for a comparative study of the ketamine isomers in surgical patients.³⁶ To assess the intraoperative and postoperative effects of the isomers compared to the racemic mixture as sole anesthetics, equianesthetic doses of racemic ketamine (2 mg/kg), (+)-ketamine (1 mg/kg) or (-)-ketamine (3 mg/kg), were administered intravenously in a randomized, double-blind manner to 60 healthy patients undergoing elective outpatient procedures. The (+)-isomer of ketamine was judged to produce more effective anesthesia than either the racemate or (-)-isomer (95 *vs.* 75 *vs.* 68 per cent, respectively). Quantification of verbal responses in the postanesthetic period suggested that more psychic emergence reactions occurred after administration of (-)-ketamine than the racemic compound or (+)-ketamine (occurrence of 53 *vs.* 15 *vs.* 5 per cent, respectively). Furthermore, the patients

** Woolf TF, Castagnoli N, Trevor AJ, et al: Unpublished data.

given (–)-ketamine demonstrated more agitation than those given the racemate or (+)-ketamine. Although it is of a preliminary nature, this double-blind study disclosed differences in anesthetic potency, physical side-effects, the incidence of postanesthetic emergence phenomena, and patient anesthetic preference between the two optical isomers of ketamine.

The fact that the individual optical isomers of ketamine do differ in their pharmacological properties supports the suggestion that the CNS effects of these compounds are exerted, at least in part, via interactions with specific receptors, although the precise nature of such "target" molecules awaits further elucidation. However, certain of the neuropharmacological differences may also result from variations between optical isomers of ketamine in terms of metabolism and biodisposition. For example, following administration of equimolar quantities of the separate isomers, they are subjected to metabolism at different rates.^{198,199} The N-demethylated compound, (+)-norketamine, has been shown to accumulate in the brain tissues of laboratory animals to a greater extent than (–)-norketamine. In contrast, the ring-hydroxylated metabolites of (–)-ketamine reach brain levels three times higher than similar metabolites of the (+)-isomer. Since these individual metabolites have yet to be studied in terms of their neuropharmacological effects, it remains possible that they may be implicated in certain of the previously described CNS effects of ketamine.

Clinical Applications

ANESTHESIA FOR BURN PATIENTS

Ketamine has been used extensively in burn units for dressing changes, debridements and skin grafting procedures in children^{201,202} and adults.¹³ Low-dose ketamine (1.5–2.0 mg/kg, im) is alleged to have a rapid onset of action and to produce good operating conditions, amnesia, and satisfactory analgesia with a rapid recovery and reestablishment of routine activities.¹⁷ However, an apparent tolerance to ketamine developed in all patients receiving more than two exposures to ketamine, and the dose had to be increased progressively in patients receiving repeated administration. Ketamine, 4.0–6.0 mg/kg, im, produced excellent surgical conditions for eschar excision.¹⁸⁷ The "rapid recovery" from ketamine allowed for a minimal delay in resuming nutritional intake. Mild emergence reactions manifested by excitement and/or illusions were noted in about 10 per cent of these unpremedicated burn patients.

ANESTHESIA FOR THE AGED AND CRITICALLY ILL

Ketamine has been useful in critically ill patients where a period of hypotension or apnea could be life-threatening. Unfortunately, it is difficult to extract ob-

jective and meaningful data from many of these uncontrolled clinical reports. When ketamine has been used in a critically ill patient population, it has been reported to provide good surgical anesthesia with a greater margin of safety than "conventional" anesthesia, with a low incidence of side-effects and postoperative complications.^{44,77,203–205} Vaughan and Stephen²⁰⁶ utilized ketamine in thoracic and abdominal surgical procedures in elderly, poor risk patients and reported hemodynamic stability and rapid emergence with a low incidence of unpleasant dreams (4 per cent). Ketamine has been regarded by some as advantageous for patients in hemorrhagic shock,^{207–209} while others have disputed its usefulness in this situation.^{112,210} Induction of ketamine anesthesia in patients who were hypovolemic secondary to acute hemorrhage caused no change or a slight increase in blood pressure and heart rate, in contrast to the marked pressor response following its administration to normovolemic subjects. In patients who had been in borderline or actual shock for several days, induction of anesthesia with ketamine produced a marked depressor response and possible maldistribution of systemic blood flow.¹¹² It is possible that prolonged preoperative stress diminishes the usual cardiovascular stimulation produced in response to ketamine, thereby unmasking its direct myocardial depressant properties.

Interesting case reports regarding the successful use of ketamine to treat severe bronchospasm refractory to conventional bronchodilators have appeared in the anesthesia literature.^{211,212} Ketamine produces an increase in pulmonary compliance and a reduction in airway resistance in patients with asthma.^{132,133} Ketamine was found to be effective in treating bronchospasm occurring during halothane anesthesia.¹³² Because of its salutary effects on airway resistance, ketamine may be the agent of choice for rapid induction of anesthesia in patients with reactive airway disease. Furthermore, ketamine is a reasonable alternative to enflurane or isoflurane in patients without significant cardiovascular diseases who are receiving parenteral bronchodilators at the time of surgery. Finally, ketamine would be advantageous in those situations where a high inspired oxygen concentration is required to maintain adequate tissue oxygenation, (*e.g.*, severe anemia).

OBSTETRICAL ANESTHESIA

Early studies utilizing ketamine for analgesia during routine vaginal deliveries demonstrated a number of maternal complications and depressed infants with low Apgar scores.^{45,47} These problems were shown to be dose-related and when lower doses of ketamine (0.2–0.5 mg/kg, iv) were utilized, the neonate was not depressed and the complications were minimal, with high patient ac-

ceptance.^{213,214} Nevertheless, when subanesthetic doses of ketamine are used to produce obstetrical analgesia, a majority of these unpremedicated patients will experience a dreamlike state. Ketamine given in combination with nitrous oxide for obstetrical anesthesia produces virtually no recall of pain during delivery and although dreaming occurred in 20 per cent of the patients, a majority of the dreams were pleasant with excellent patient acceptance.²¹⁵ The use of larger doses of ketamine (1.5 mg/kg, iv) for induction of anesthesia in unpremedicated parturients produced good surgical anesthesia; unfortunately, recovery from anesthesia was unpleasant in over 50 per cent of the cases.²¹⁶ In a large obstetrical series comparing low-dose ketamine (0.5 mg/kg, iv) with methoxyflurane (0.25–10 per cent), ketamine produced a more rapid onset of action and proved to be the superior analgesic with comparable patient acceptance.²¹⁷ However, ketamine produced a significant incidence of unpleasant dreams and the use of droperidol as an adjunctive agent prolonged the recovery period without decreasing the incidence of emergence reactions.

When compared to thiopental, ketamine provided a rapid induction, greater analgesia and amnesia with a comparable incidence of unpleasant emergence reactions when used for induction of anesthesia for cesarean section.¹⁵³ Moreover, the incidence of undesirable psychotomimetic responses is low following either ketamine or thiopental administration for cesarean section.^{45,218,219} Using ketamine as the sole anesthetic for cesarean section, Bunodiére *et al.*²²⁰ reported that fetal mortality was less than half that seen with other general anesthetic techniques. Furthermore, ketamine might be a useful analgesic for managing the preeclamptic patient because of its anticonvulsant properties.²²¹

There have been no reports at the clinical level on fetal acid/base changes following ketamine anesthesia; however, animal studies indicate that ketamine increases uterine blood flow and does not produce deleterious effects on fetal cardiovascular or acid/base status.²²² Evaluation of arterial blood gases in mothers and infants during ketamine analgesia for vaginal delivery, showed no significant differences between the ketamine group and a comparable group receiving regional anesthesia.¹²⁹ A comparison of ketamine and thiopental for rapid iv induction prior to cesarean section showed a greater maternal umbilical artery and vein pH and a larger base excess value following ketamine.²¹⁹ Neonatal arterial blood pressure has been reported to be less depressed after maternal ketamine anesthesia compared to a similar group receiving thiopental.²²³ Neonatal neurobehavioral tests following vaginal delivery under ketamine, 0.7 mg/kg, iv, with 50 per cent nitrous oxide, thiopental, 4 mg/kg, iv, with 50 per cent nitrous oxide or chloroprocaine

epidural anesthesia, revealed the greatest percentage of high scores in the epidural group, the lowest scores after thiopental–N₂O and intermediate values following ketamine–nitrous oxide.²²⁴

OUTPATIENT ANESTHESIA

Children. Low-dose ketamine has been used successfully for brief pediatric oral surgery procedures lasting from 5 to 30 minutes, utilizing doses of 1–3 mg/kg, im, and 0.5–1.0 mg/kg, iv.^{225,226} However, others have reported significant cardiovascular stimulation, partial airway obstruction and minor post-anesthetic complications, including unpleasant dreams.²²⁷

Intramuscular ketamine, 5–10 mg/kg, has proved useful for diagnostic and minor surgical procedures which may not require intravenous cannulae or endotracheal intubation.¹⁸² There is a high degree of acceptance of ketamine in children undergoing repeated anesthetics, including its use in radiotherapy.^{185,186} In children undergoing minor otolaryngological procedures, ketamine (2 mg/kg, iv) compared favorably with thiopental (4 mg/kg, iv) and althesin (0.55 mg/kg).²²⁸ Operating conditions were similar in all groups; however, thiopental and althesin produced more cardiorespiratory depression and a greater need for postoperative analgesics, while ketamine was associated with a higher incidence of restlessness and a somewhat more prolonged recovery. Ketamine, 10 mg/kg, im, has reportedly been used for bronchoscopy in children without significant complications.²³⁴ However, ketamine stimulates production of copious amounts of upper airway secretions, necessitating concomitant use of an antisialogogue. Furthermore, anecdotal reports indicate that ketamine may produce “hyperreactive” airway reflexes, especially in the presence of inflammation of the upper respiratory tract. The use of ketamine for ocular examinations under anesthesia has been widely accepted in spite of occasional problems during the recovery phase.²²⁹ Although early clinical reports suggested that there was an increase in intraocular pressure with ketamine,^{230,231} more recent studies have found this not to be the case.^{232,233} Finally, rectal ketamine, 8–10 mg/kg, has been used successfully as an induction agent in pediatric anesthesia.²³⁵

Adults. In a large series comparing low-dose ketamine (0.5 mg/kg, iv) with methohexital (1 mg/kg, iv) in combination with nitrous oxide for minor gynecologic procedures,⁵⁸ ketamine was associated with fewer intraoperative problems. However, in patients premedicated with droperidol the ketamine-induced dreams were more vivid and unpleasant than those associated with methohexital. Although pentobarbital (1.5 mg/kg, im or iv) reduced the incidence of psychic emergence reactions

after ketamine, the recovery period was prolonged with concomitant barbiturate administration.²³⁶ In a double-blind study comparing ketamine with Innovar® in combination with N₂O/O₂ for gynecologic procedures, the effects of ketamine could not be differentiated clinically from those of Innovar®.²³⁷ However, fewer intraoperative and postoperative complications were reported after ketamine, while the degree of respiratory depression and the need for postoperative analgesics was higher in the Innovar® group. In our series evaluating the effectiveness of racemic ketamine alone (average total dose equalled 5.4 mg/kg, iv) for midtrimester abortions,³⁶ ketamine was found to be inadequate in 25 per cent of the cases. Commonly reported side-effects included visual distortions (45 per cent), dizziness/lightheadedness (35 per cent), and agitation/disorientation (30 per cent). Overall, 85 per cent of the patients experienced dreams (70 per cent of which were pleasant experiences), and 35 per cent stated that they would prefer a different anesthetic in the future. Although recovery was occasionally prolonged, most patients were discharged within 2 hours of awakening from the anesthetic. Others have utilized low doses of ketamine for brief gynecological procedures with highly satisfactory operating conditions, few postanesthetic side-effects and a rapid recovery from anesthesia.^{66,75,238} In summary, it appears that ketamine can be used successfully for outpatient anesthesia if minimal effective doses are administered (ketamine 0.5–1.5 mg/kg iv for induction followed by continuous infusion of 10–20 $\mu\text{g} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$) in combination with diazepam, 0.2–0.3 mg/kg, iv (or flunitrazepam 0.01–0.02 mg/kg, iv), and nitrous oxide in oxygen. However, the concomitant use of benzodiazepines with long elimination half-life values will prolong recovery from ketamine anesthesia. In order to provide for a more rapid recovery following brief outpatient procedures, we are utilizing a combination of 3–4 mg/kg thiopental, iv (or 1–2 mg/kg methohexital, iv) for induction followed by a continuous infusion of ketamine with nitrous oxide in oxygen.

ADJUNCT TO LOCAL AND REGIONAL ANESTHESIA

During the performance of a painful nerve block, the ideal premedicant drug would provide analgesia, sedation and amnesia without cardiorespiratory embarrassment. Thompson and Moore²³⁹ compared the clinical effectiveness and acceptability of ketamine (2 mg/kg, iv) with diazepam (20 mg, im, and 20 mg, iv) and Innovar® (2 ml im and 3 ml iv) for sedation and analgesia prior to intercostal nerve blocks. Diazepam produced amnesia in 85 per cent of the patients (15 per cent recalled painful, unpleasant experiences); however, the sedation was judged by the anesthesiologist to be inadequate in over half of the cases. In the Innovar® group, 60 per cent of the patients were inadequately sedated (with frequent

signs of respiratory depression), while 40 per cent recalled the block as a painful and unpleasant experience. Ketamine produced excellent sedation and patient acceptance; however, a 10 per cent incidence of unpleasant dreams was reported in these unpremedicated patients. Kortilla and Levanen⁶⁵ examined the untoward effects of ketamine combined with diazepam for supplementation of regional anesthesia. The use of ketamine 0.5 mg/kg, iv, combined with diazepam 0.15 mg/kg, iv, was not associated with any more side effects or a greater need for postoperative care than an unpremedicated control group undergoing similar nerve block procedures, and patient acceptance was significantly higher in the diazepam-ketamine group. Use of low-dose ketamine in combination with diazepam or flunitrazepam prior to injection of local anesthetics has become increasing popular for outpatient cosmetic surgical procedures.^{75,240} Patients are reported to be comfortable, cooperative and highly satisfied with this combination. Our own experience would indicate a significant number of such patients experience dreamlike, floating sensations and even occasional unpleasant emergence reactions.

CARDIOTHORACIC ANESTHESIA

Extensive experience with ketamine for pediatric cardiac catheterizations has shown it to be highly effective with fewer catheter-associated arrhythmias than other general anesthetics.^{204,241,242} Interestingly, when ketamine was used for adult cardiac catheterization it produced a significant decrease in blood pressure in 22 per cent of the patients.²⁴³ When ketamine was administered utilizing a continuous infusion technique in combination with high-dosediazepam and N₂O/O₂, Hatano *et al.*²⁴⁴ reported that anesthesia was smooth and simple with minimal effect on the cardiorespiratory system, excellent antegrade amnesia, satisfactory analgesia and no postoperative emergence reactions. Diazepam, 0.3–0.5 mg/kg, iv, was effective in preventing a rise in the rate-pressure product following administration of ketamine to patients with coronary artery disease.¹¹⁶ In a study comparing a morphine–diazepam–nitrous oxide combination with ketamine–nitrous oxide anesthesia for coronary bypass surgery, Reves *et al.*²⁴⁵ found that although the incidence of hemodynamic changes in the rate-pressure product were similar, the mean maximal increases in systolic blood pressure and the rate-pressure product were significantly higher in the ketamine group. These investigators found no significant difference in the two anesthetic techniques in terms of perioperative morbidity and mortality. In a controlled study of the circulatory responses during induction and maintenance of anesthesia in patients undergoing heart-valve replacement, Dhadhale *et al.*²⁴⁶ found no significant differences between the ketamine–diazepam/N₂O and morphine/N₂O tech-

TABLE 2. Chronological Summary of Clinical Studies Using Continuous Infusion Techniques for Administering Ketamine

Investigator and Reference	Surgical Procedure	Premedication	Induction Agents		Maintenance Agents		Cardiovascular Stimulation*	Emergence Reactions*
			Adjuncts (mg/kg)	Ketamine (mg/kg)	Ketamine $\mu\text{g}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$	Adjuncts (Per Cent)		
Oduntan and Gool (1970) ⁴⁴	general	0	0	1.0-1.2	25-33	O ₂ (100)	++	+
Little <i>et al.</i> (1972) ⁴⁷	obstetrical	0	0	1.5-2.2	80-110	O ₂ (100)	+++	++
Jastak and Gorretta (1973) ²²⁷	oral	diazepam 5-10 mg	0	0.5-1.0	65-70	N ₂ O/O ₂ (50/50)	++	+
Vaughan and Stephens (1974) ²⁰⁶	thoraco-abdominal†	0	0	2.0	18-20	N ₂ O/O ₂ (50/50)	++	+
Ito and Ichihyanagi (1974) ²⁴⁹	postoperative pain	secobarbitone 100 mg hydroxyzine 50 mg	0	0	25	O ₂ (100)	0	0
Haiano <i>et al.</i> (1976) ²⁴⁴	cardiac	diazepam 10-15 mg	diazepam 0.3-0.5	1.0	12	N ₂ O/O ₂ (50/50)	0	0
El-Naggar <i>et al.</i> (1977) ²³⁷	gynecological	diazepam 10 mg	0	0.3	17-34	N ₂ O/O ₂ (66/34)	+	0
Hatano <i>et al.</i> (1978) ²⁵¹	abdominal	hydroxyzine 50-100 mg or diazepam 7.5-15 mg	diazepam 0.2-0.3	1.3-2.0	10-15	N ₂ O/O ₂ (66/34)	+	0
Houlton and Downing (1978) ⁷³	abdominal	omnopon 10-15 mg	flunitrazepam 0.03	0	33	O ₂ (100)	0	0
Jackson <i>et al.</i> (1978) ¹¹⁶	cardiac	morphine sulfate 5-15 mg	diazepam 0.4	2.0	90	O ₂ (100)	0	0
Kamm and Beves (1978) ²⁵²	general	haloperidol 0.1 mg/kg	0	0.5-1.0	14-28	O ₂ (100)	++	++
Lilburn <i>et al.</i> (1978) ²⁵³	plastics-gynecological	lorazepam 4 mg	0	1.0	66-83	O ₂ (100)	++	0
Dhadphale <i>et al.</i> (1979) ²⁴⁵	cardiac	morphine sulfate 5-10 mg	diazepam 0.4	2.0	17	N ₂ O/O ₂ (50/50)	+	0
Idvall <i>et al.</i> (1979) ⁷⁷	abdominal†	atropine 0.5 mg	0	2.0	41	N ₂ O/O ₂ (50/50)	++	+
Wilson <i>et al.</i> (1979) ²⁵⁴	general	diazepam 0.1 mg/kg	diazepam 0.2-0.3	1.0	64	N ₂ O/O ₂ (66/34)	0	0
Barclay <i>et al.</i> (1980) ⁷⁴	gynecological	papaveretum 10-15 mg atropine 0.6 mg	flunitrazepam 0.03	0	16-31	N ₂ O/O ₂ (40/60)	+	+
Pandit <i>et al.</i> (1980) ²⁵⁵	none	atropine 0.3 mg diazepam 0.2 mg/kg	0	1.0	8-17	0	+	+

* Relative scale: 0 = none or minimal, + = mild, ++ = moderate, +++ = severe. † Elderly, high-risk patient populations.

TABLE 3. General Recommendations for the Use of Ketamine as a Sedative, Analgesic and Anesthetic Agent

- 1) Premedication: A benzodiazepine administered either orally (*e.g.*, diazepam, 15–30 mg, lorazepam, 2–5 mg) 60–90 min before surgery or smaller doses iv immediately prior to induction as an adjunct to ketamine. If preoperative sedation is contraindicated, a benzodiazepine can be administered iv prior to the termination of surgery. A noncentrally active antisialogogue (*e.g.*, glycopyrrolate, 0.005 mg/kg, iv) administered 5–10 min prior to induction.
- 2) Induction of anesthesia: Ketamine, 0.5–1.5 mg/kg, iv, or 4–6 mg/kg, im. Lower doses of ketamine are used if thiopental (1–2 mg/kg, iv) is used as an adjunct in place of the benzodiazepine or if the patient is critically ill.
- 3) Maintenance of anesthesia: Ketamine, 10–30 $\mu\text{g}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ (1–2 mg/min) via continuous iv infusion. If high concentrations of inspired oxygen are not required to maintain adequate tissue oxygenation, supplemental N_2O 50–70 per cent in oxygen will reduce the ketamine requirement.
- 4) Sedation and analgesia: Ketamine, 0.2–0.75 mg/kg, iv (over 2–3 min) or 2–4 mg/kg, im, followed by continuous ketamine infusion 5–20 $\mu\text{g}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ with or without supplemental oxygen.

niques. It would appear that high-dose diazepam (0.5 mg/kg, iv) in combination with ketamine (1–2 mg/kg for induction and 15–30 $\mu\text{g}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$ for maintenance) is a satisfactory alternative to morphine– N_2O anesthesia for patients with coronary artery disease as well as for those undergoing heart valve replacement. A potential advantage of the diazepam/ketamine technique is that the nitrous oxide concentration is not critical and therefore 100 per cent oxygen can be utilized.

When used for induction of anesthesia in patients with valvular heart disease ketamine produced increases in pulmonary vascular resistance and increased the minute work of the heart.²⁴⁷ Thus, ketamine might be deleterious to patients with limited right ventricular functional reserve (*e.g.*, pulmonary emboli). However, many cardiac anesthesiologists consider ketamine the drug of choice for induction and maintenance of anesthesia in patients with cardiac tamponade or constrictive pericarditis because of its ability to maintain sympathetic nervous system activity, even though the pulmonary vascular resistance may be further increased by ketamine. Finally, when one-lung anesthesia is utilized during thoracic surgery, patients with impaired pulmonary function are reportedly improved with regard to PaO_2 and calculated pulmonary shunt fraction when a diazepam–ketamine–relaxant oxygen anesthetic technique is compared to a conventional inhalational technique.²⁴⁸

Conclusions

Ketamine is a safe, rapid-acting parenteral anesthetic and analgesic agent which has been in clinical use for more than 10 years. In early investigations, it was noted that ketamine produced marked elevations in blood pressure and heart rate, profuse salivation, lacrimation, dia-

TABLE 4. Clinical Uses of Ketamine and Contraindications to Its Use

- I. Indications for ketamine anesthesia or analgesia
 - A. Aged and poor-risk patients:
 1. shock or cardiovascular instability
 2. severe dehydration
 3. respiratory failure or bronchospasm
 4. severe anemia
 5. major thoracoabdominal procedures
 6. cardiac tamponade and constrictive pericarditis
 - B. Obstetrical patients:
 1. rapid induction of general anesthesia
 - a. severe hypovolemia
 - b. acute hemorrhage
 - c. acute bronchospasm
 2. low-dose for analgesia
 - a. supplement regional technique
 - b. transient analgesia at the time of delivery or during postpartum period
 - C. Adjunct to local and regional anesthetic techniques:
 1. low-dose for sedation and analgesia during performance of nerve block procedure
 2. supplemental analgesia for inadequate block
 - D. Outpatient surgery:
 1. Pediatric anesthesia
 - a. brief diagnostic and therapeutic procedures (*e.g.*, cardiac cath; endoscopy; oral surgery; head and neck surgery; orthopedic surgery; ophthalmology; radiotherapy)
 - b. induction of anesthesia (*e.g.*, intramuscular or rectal route)
 2. Adult anesthesia
 - a. brief surgical procedures (*e.g.*, gynecological, head and neck, orthopedic, urologic)
 - b. supplement local and regional techniques
 - c. diagnostic and therapeutic procedures (*e.g.*, endoscopy)
 - E. Patients with reactive airway disease:
 1. asthmatics with acute bronchospasm
 2. chronic obstructive pulmonary disease with bronchospasm
 - F. Patients with thermal injuries:
 1. debridement and skin grafting
 2. dressing changes
 - G. Postoperative analgesia:
 1. recovery room
 2. intensive care units
- II. Contraindications to the use of ketamine
 - A. Cardiovascular disease:
 1. poorly controlled hypertension
 2. intracranial, thoracic or abdominal aneurysms
 3. unstable angina or recent myocardial infarction
 4. right or left heart failure
 - B. Central nervous system disorders:
 1. cerebral trauma
 2. intracerebral mass or hemorrhage
 - C. Open-globe injury to eye or increased intraocular pressure*
 - D. Thyrotoxic states*
 - E. Otolaryngologic procedures involving pharynx, larynx or trachea*
 - F. Psychiatric disorders (*e.g.*, schizophrenia) or history of adverse reaction to ketamine or one of its congeners*

* Indicates a *relative* contraindication to the use of ketamine.

phoresis, skeletal muscle hypertonus, involuntary purposeless movements, and agitation or even frank delirium during emergence. Subsequent studies have shown that benzodiazepines, are highly effective in preventing the marked cardiovascular responses and unpleasant emergence reactions associated with ketamine anesthesia. Furthermore, by utilizing a continuous infusion technique the anesthetist can titrate the drug more closely and thereby reduce the amount of drug administered. In table 2 we have summarized the clinical studies which have appeared in the literature during the last ten years using a variety of adjunctive ketamine infusion techniques. The information contained in table 2 indicate the efficacy of various adjunctive agents in attenuating the adverse cardiovascular and psychic emergence reactions associated with ketamine anesthesia. Utilizing this information and our own clinical experience with ketamine, we have developed table 3 which summarizes our general recommendations regarding the use of ketamine.

It is obvious that many of the goals desirable in an ideal intravenous anesthetic (table 1) have not been reached with currently available agents. In fact, ketamine is the only available iv agent which can function as a sole anesthetic (without requiring adjunctive agents) because of its unique sedative, amnestic, analgesic, and anesthetic properties. How well then do racemic ketamine and its (+) isomer compare to the ideal iv anesthetic agent? In terms of physical properties, both of these drugs possess all the desired properties. They are water-soluble, stable in solution, and painless and nonirritating following par-enteral injection. Racemic ketamine produces a rapid onset of action, frequent excitatory activity and hypertonus, minimal (if any) cardiorespiratory depression, analgesia, amnesia, rare (if any) hypersensitivity reactions, and a relatively rapid recovery with frequent emergence reactions. S(+)-ketamine has similar anesthetic properties, however, it is associated with a lower incidence of excitatory motor activity, less marked tachycardia, and a smoother recovery without emergence excitement or delirium. Although (+)-ketamine comes very close to the ideal, it seems unlikely that a single drug will be developed which will possess all the properties desired in the ideal iv agent. The use of iv anesthetic techniques utilizing combinations of short-acting compounds with mutually complementary pharmacologic properties allows for more control in terms of the depth and duration of anesthesia, while reducing the potential for adverse drug interactions in the postoperative period. We would speculate that combining S(+)-ketamine with midazolam, a water-soluble benzodiazepine possessing a pharmacokinetic profile similar to that of ketamine, would produce an ideal iv anesthetic combination.

We see potential clinical applications for adjunctive ketamine techniques in anesthesia for major surgery and outpatient anesthesia (as an anesthetic, analgesic, and

sedative adjunct during general, regional and local anesthesia), as well as increased use in the recovery area for postoperative pain relief.^{249,250} The current clinical uses of ketamine as well as the contraindications to its use are summarized in table 4. It should be noted that in several areas the indications and contraindications are not supported by well-controlled clinical studies.

It has been our intent in this review to bring the pharmacologic information available on ketamine into focus and to then use this information as a background upon which to discuss ketamine's potential clinical uses. It is apparent that this drug is not the ideal intravenous anesthetic; however, its many useful pharmacologic properties hopefully will spur the search for agents which will be closer to the ideal.

References

1. Greifenstein FE, Devault M, Yoshitake J: A study of l-aryl cyclohexylamine for anesthesia. *Anesth Analg (Cleve)* 37:283-294, 1958
2. Johnstone M, Evans V, Baigel S: Sernyl (CI-395) in clinical anaesthesia. *Br J Anaesth* 31:433-439, 1959
3. Collins VJ, Gorospe CA, Rovenstine CA: Intravenous non-barbiturate, nonnarcotic analgesics: Cyclohexylamines. *Anesth Analg (Cleve)* 39:302-306, 1960
4. Domino EF, Chodoff P, Corssen G: Pharmacologic effects of CI-581, a new dissociative anesthetic in man. *Clin Pharmacol Ther* 6:279-291, 1965
5. Cohen ML, Trevor AJ: On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects. *J Pharmacol Exp Ther* 189:351-358, 1974
6. Corssen G, Miyasaka M, Domino EF: Changing concepts in pain control during surgery: Dissociative anesthesia with CI-581. *Anesth Analg (Cleve)* 47:746-759, 1968
7. Harris JA, Biersner RJ, Edwards D, et al: Attention, learning and personality during ketamine emergence. *Anesth Analg (Cleve)* 54:169-172, 1975
8. Kayama Y, Iwama K: The EEG, evoked potentials, and single-unit activity during ketamine anesthesia in cats. *ANESTHESIOLOGY* 36:316-328, 1972
9. Corssen G, Little SG, Tavakoli M: Ketamine and epilepsy. *Anesth Analg (Cleve)* 53:319-335, 1974
10. Ferrer-Allado T, Brechner VL, Dymond A, et al: Ketamine-induced electroconvulsive phenomena in the human limbic and thalamic regions. *ANESTHESIOLOGY* 38:333-344, 1973
11. Celesia GG, Chen RC, Bamforth BJ: Effects of ketamine in epilepsy. *Neurology* 25:169-172, 1975
12. Reder BS, Trapp LD, Troutman KC: Ketamine suppression of chemically induced convulsions in the two-day-old white leghorn cockerel. *Anesth Analg (Cleve)* 59:406-409, 1980
13. Bjarnesen W, Corssen G: CI-581: A new non-barbiturate short-acting anesthetic for surgery in burns. *Mich Med* 66:177-181, 1967
14. Aguado-Matorras A, Nalda-Felipe MA, Vidal-Macho J, et al: Experiencia personal de 300 casos de CI-581 (ketamina) en anestesiología. *Rev Esp Anestesiología Reanim* 17:302-317, 1970
15. Bovill JG, Dundee JW: Alterations in response to somatic pain associated with anesthesia-ketamine. *Br J Anaesth* 43:496-499, 1971
16. Sadove MS, Shulman M, Hatano S, et al: Analgesic effects of ketamine administered in subdissociative doses. *Anesth Analg (Cleve)* 50:452-457, 1971
17. Slogoff S, Allen GW, Wessels JV, et al: Clinical experience with subanesthetic ketamine. *Anesth Analg (Cleve)* 53:354-358, 1974

18. Massopust LC Jr, Wolin LR, Albin MS, et al: Electrophysiologic and behavioral responses to ketamine hydrochloride in the rhesus monkey. *Anesth Analg (Cleve)* 51:329-341, 1972
19. Sparks DL, Corssen G, Sides J, et al: Ketamine-induced anesthesia: Neural mechanisms in the rhesus monkey. *Anesth Analg (Cleve)* 52:288-297, 1973
20. Sparks DL, Corssen G, Aizenman B, et al: Further studies of the neural mechanisms of ketamine-induced anesthesia in the rhesus monkey. *Anesth Analg (Cleve)* 54:189-195, 1975
21. Ohtani M, Kikuchi H, Kitahata LM, et al: Effects of ketamine on nociceptive cells in the medial medullary reticular formation of the cat. *ANESTHESIOLOGY* 51:414-417, 1979
22. Conseiller C, Benoist JM, Hamann KF, et al: Effects of ketamine (CI 581) on cell responses to cutaneous stimulations in laminae IV and V in the cat's dorsal horn. *Eur J Pharmacol* 18:346-352, 1972
23. Kitahata LM, Taub A, Kosaka Y: Lamina-specific suppression of dorsal-horn unit activity by ketamine hydrochloride. *ANESTHESIOLOGY* 38:4-11, 1973
24. Tang AH, Schroeder LA: Spinal cord depressant effects of ketamine and etoxadrol in the cat and the rat. *ANESTHESIOLOGY* 39:37-43, 1973
25. Vincent JP, Corey D, Kamenka JM, et al: Interaction of phenylcyclidines with the muscarinic and opiate receptors in the central nervous system. *Brain Res* 152:176-182, 1978
26. Finck AD, Ngai SH: A possible mechanism of ketamine-induced analgesia. *ANESTHESIOLOGY* 51:S34, 1979
27. Smith DJ, Westfall DP, Adams JD, et al: Ketamine interacts with opiate receptors as an agonist. *ANESTHESIOLOGY* 53:S5, 1980
28. Fratta W, Casu M, Balestrieri A, et al: Failure of ketamine to interact with opiate receptors. *Eur J Pharmacol* 61:389-391, 1980
29. Cohen ML, Chan SL, Bhargava HN, et al: Inhibition of mammalian brain acetylcholinesterase by ketamine. *Biochem Pharmacol* 23:1647-1652, 1974
30. Ngai SH, Cheney DL, Finck AD: Acetylcholine concentrations and turnover in rat brain structures during anesthesia with halothane, enflurane and ketamine. *ANESTHESIOLOGY* 48:4-10, 1978
31. Balmer HGR, Wyte SR: Antagonism of ketamine by physostigmine. *Br J Anaesth* 49:510, 1977
32. Lawrence D, Livingston A: The effect of physostigmine and neostigmine on ketamine anaesthesia and analgesia. *Br J Pharmacol* 67:426, 1979
33. Toro-Matos A, Rendon-Platas AM, Avila-Valdez E, et al: Physostigmine antagonizes ketamine. *Anesth Analg (Cleve)* 59:764-767, 1980
34. Drummond JC, Brebner J, Galloon S, et al: A randomized evaluation of the reversal of ketamine by physostigmine. *Can Anaesth Soc J* 26:288-295, 1979
35. Agoston S, Salt PJ, Erdmann W, et al: Antagonism of ketamine-diazepam anaesthesia by 4-aminopyridine in human volunteers. *Br J Anaesth* 52:367-370, 1980
36. White PF, Ham J, Way WL, et al: Pharmacology of ketamine isomers in surgical patients. *ANESTHESIOLOGY* 52:231-239, 1980
37. Fine J, Finestone SC: Sensory disturbances following ketamine anesthesia—Recurrent hallucinations. *Anesth Analg (Cleve)* 52:428-430, 1973
38. Perel A, Davidson JT: Recurrent hallucinations following ketamine. *Anaesthesia* 31:1081-1083, 1976
39. Meyers EF, Charles P: Prolonged adverse reactions to ketamine in children. *ANESTHESIOLOGY* 49:39-40, 1978
40. Nelson SR, Howard RB, Cross RS, et al: Ketamine-induced changes in regional glucose utilization in the rat brain. *ANESTHESIOLOGY* 52:330-334, 1980
41. Crosby G, Tannenbaum A, Sokoloff L, et al: Ketamine alters regional glucose utilization in rat brain. *ANESTHESIOLOGY* 53:S6, 1980
42. Collier BB: Ketamine and the conscious mind. *Anaesthesia* 27:120-134, 1972
43. Hejja P, Galloon S: A consideration of ketamine dreams. *Can Anaesth Soc J* 22:100-105, 1975
44. Oduntan SA, Gool RY: Clinical trial of ketamine (CI-581) *Can Anaesth Soc J* 17:411-416, 1970
45. Moore J, McNabb TG, Dundee JW: Preliminary report on ketamine in obstetrics. *Br J Anaesth* 43:779-782, 1971
46. Knox JWD, Bovill JG, Clarke RSJ, et al: Clinical studies of induction agents-ketamine. *Br J Anaesth* 42:875-885, 1970
47. Little B, Chang T, Chucot L, et al: Study of ketamine as an obstetric anesthesia agent. *Ann J Obstet Gynecol* 113:247-260, 1972
48. Krestow M: The effect of post-anaesthetic dreaming on patient acceptance of ketamine anaesthesia: A comparison with thiopentone-nitrous oxide anaesthesia. *Can Anaesth Soc J* 21:385-389, 1974
49. Sussman DR: A comparative evaluation of ketamine anesthesia in children and adults. *ANESTHESIOLOGY* 40:459-464, 1974
50. Bovill JG, Dundee JW, Coppel L, et al: Current status of ketamine anaesthesia. *Lancet* 1:1285-1288, 1971
51. Dundee JW, Bovill JG, Clarke RSJ, et al: Problems with ketamine in adults. *Anaesthesia* 26:86, 1971
52. Wulfsohn NL: Ketamine dosage for induction based on lean body mass. *Anesth Analg (Cleve)* 51:299-305, 1972
53. Khorramzadeh E, Lotfy AO: Personality predisposition and emergence phenomena with ketamine. *Psychosomatics* 17:94-95, 1976
54. Garfield JM, Garfield FB, Stone JG, et al: A comparison of psychologic responses to ketamine and thiopental-nitrous oxide-halothane anesthesia. *ANESTHESIOLOGY* 36:329-338, 1972
55. Modvig KM, Nielsen SF: Psychological changes in children after anesthesia: A comparison between halothane and ketamine. *Acta Anaesth Scand* 21:541-544, 1977
56. Morgan M, Loh L, Singer L: Ketamine as the sole anaesthetic agent for minor surgical procedures. *Anaesthesia* 26:158-165, 1971
57. Erbguth PH, Reiman B, Klein RL: The influence of chlorpromazine, diazepam and droperidol on emergence from ketamine. *Anesth Analg (Cleve)* 51:693-700, 1972
58. Figallo EM, Casali H, McKenzie R, et al: Ketamine as the sole anaesthetic agent for laparoscopic sterilization. *Br J Anaesth* 49:1159-1165, 1977
59. Sadove MS, Hatano S, Zahed B, et al: Clinical study of droperidol in the prevention of the side effects of ketamine anesthesia: A preliminary report. *Anesth Analg (Cleve)* 50:388-393, 1971
60. Krantz ML: Ketamine in obstetrics: Comparison with methoxyflurane. *Anesth Analg (Cleve)* 53:890-893, 1974
61. Liang HS, Liang HG: Minimizing emergence phenomena: Subdissociative dosage of ketamine in balanced surgical anesthesia. *Anesth Analg (Cleve)* 54:312-316, 1975
62. Bidwai AV, Stanley TH, Graves CL, et al: The effects of ketamine on cardiovascular dynamics during halothane and enflurane anesthesia. *Anesth Analg (Cleve)* 54:588-592, 1975
63. El-Naggar M, Kintanar D, Rodenas J, et al: Ketamine as an induction agent and an adjunct to nitrous oxide-oxygen curare anesthesia sequence. *Anesthesiol Rev* 4:10-16, 1975
64. Kothary SP, Zsigmond EK: A double-blind study of the effective antihallucinatory doses of diazepam prior to ketamine anesthesia. *Clin Pharmacol Ther* 21:108-109, 1977
65. Korttila K, Levanen J: Untoward effects of ketamine combined with diazepam for supplementing conduction anaesthesia in young and middle-aged adults. *Acta Anaesth Scand* 22:640-648, 1978
66. Ayim EN, Makatia FX: The effects of diazepam on ketamine anaesthesia. *East Afr Med J* 53:377-382, 1976
67. Mattila MAK, Larni HM, Nummi SE, et al: Effect of diazepam on emergence from ketamine anaesthesia: A double-blind study. *Anaesthesist* 28:20-23, 1979
68. Dundee JW, Lilburn JK: Ketamine-lorazepam: Attenuation of the psychic sequelae of ketamine by lorazepam. *Anaesthesia* 37:312-314, 1977
69. Lilburn JK, Dundee JW, Nair SG, et al: Ketamine sequelae-

- Evaluation of the ability of various premedicants to attenuate its psychic actions. *Anaesthesia* 33:307-311, 1978
70. Fragen RJ, Caldwell N: Lorazepam premedication-Lack of recall and relief of anxiety. *Anesth Analg (Cleve)* 55:792-796, 1976
71. Dundee JW, McGowan AW, Lilburn JK, et al: Comparison of the actions of diazepam and lorazepam. *Br J Anaesth* 51:439-445, 1979
72. Kothary SP, Pandit SK: Orally administered diazepam and lorazepam-Sedative and amnesic effects. *ANESTHESIOLOGY* 53:S18, 1980
73. Houlton PJC, Downing JW: General anaesthesia with intravenous flunitrazepam, continuous ketamine infusion and muscle relaxant. *S Afr Med J* 54:1048-1049, 1978
74. Barclay A, Houlton PC, Downing JW: Total intravenous anaesthesia—A technique using flunitrazepam, ketamine, muscle relaxants and controlled ventilation of the lung. *Anaesthesia* 35:287-290, 1980
75. Rothe KF, Schorer R: Ataranalgesia—an intravenous anesthetic technique: Experience with 978 administrations. *Acta Anaesth Belg* 31:77-89, 1980
76. Tweed WA, Minuck MS, Mymin D: Circulatory responses to ketamine anaesthesia. *ANESTHESIOLOGY* 37:613-619, 1972
77. Idvall J, Ahlgren I, Aronsen KF, et al: Ketamine infusions: Pharmacokinetics and clinical effects. *Br J Anaesth* 51:1167-1172, 1979
78. Dowdy EG, Kaya K: Studies of the mechanism of cardiovascular responses to CI-581. *ANESTHESIOLOGY* 29:931-943, 1968
79. Slogoff S, Allen GW: The role of baroreceptors in the cardiovascular response to ketamine. *Anesth Analg (Cleve)* 53:704-707, 1974
80. McGrath JC, MacKenzie JE, Miller RA: Effects of ketamine on central sympathetic discharge and the baroreceptor reflex during mechanical ventilation. *Br J Anaesth* 47:1141-1147, 1975
81. Traber DL, Wilson RD, Priano LL, et al: Blockade of the hypertensive response to ketamine. *Anesth Analg (Cleve)* 49:420-426, 1970
82. Ivankovich AD, Miletich DJ, Reimann C, et al: Cardiovascular effects of centrally administered ketamine in goats. *Anesth Analg (Cleve)* 53:924-933, 1974
83. Chodoff P: Evidence for central adrenergic action of ketamine. *Anesth Analg (Cleve)* 51:247-250, 1972
84. Wong DHW, Jenkins LC: An experimental study of the mechanism of action of ketamine on the central nervous system. *Can Anaesth Soc J* 21:57-67, 1974
85. Traber DL, Wilson RD, Priano LL: Differentiation of the cardiovascular effects of CI-581. *Anesth Analg (Cleve)* 47:769-778, 1968
86. Schwartz DA, Horwitz LD: Effects of ketamine on left ventricular performance. *J Pharmacol Exp Ther* 194:410-414, 1975
87. Goldberg AH, Keane PW, Phear WPC: Effects of ketamine on contractile performance and excitability of isolated heart muscle. *J Pharmacol Exp Ther* 175:388-394, 1970
88. Berry DG: Effect of ketamine on the isolated chick embryo heart. *Anesth Analg (Cleve)* 53:919-923, 1974
89. Davies AE, McCane JL: Effects of barbiturate anesthetics and ketamine on the force-frequency relation of cardiac muscle. *Eur J Pharmacol* 26:65-73, 1979
90. Hill GE, Wong KC, Shaw CL, et al: Interactions of ketamine with vasoactive amines at normothermia and hypothermia in the isolated rabbit heart. *ANESTHESIOLOGY* 48:315-319, 1978
91. Hamilton JT, Bryson JS: The effect of ketamine on transmembrane potentials of Purkinje fibers of the pig heart. *Br J Anaesth* 46:636-642, 1974
92. Koehntop DE, Liao J-C, Van Bergen FH, et al: Effects of pharmacologic alterations of adrenergic mechanisms by cocaine, tropolone, aminophylline and ketamine on epinephrine-induced arrhythmias during halothane-nitrous oxide anesthesia. *ANESTHESIOLOGY* 46:89-93, 1977
93. Ivankovich AD, El-Etr AA, Janeczko GF, et al: The effects of ketamine and of Innovar® anesthesia on digitalis tolerance in dogs. *Anesth Analg (Cleve)* 54:106-111, 1975
94. Clanachan AS, McGrath JC: Effects of ketamine on the peripheral autonomic nervous system of the rat. *Br J Pharmacol* 58:247-252, 1976
95. Byrne AJ, Healy TEJ, Tomlinson DR: The effects of ketamine on nonadrenergic transmission and the response to nonadrenaline in rat smooth muscle. *Br J Pharmacol* 67:462, 1979
96. Juang MS, Konemura K, Morioka T, et al: Ketamine acts on the peripheral sympathetic nervous system of guinea pigs. *Anesth Analg (Cleve)* 59:45-49, 1980
97. Miletich DJ, Ivankovic AD, Albrecht RF, et al: The effect of ketamine on catecholamine metabolism in the isolated perfused rat heart. *ANESTHESIOLOGY* 39:271-277, 1973
98. Nedergaard OA: Cocaine-like effect of ketamine on vascular adrenergic neurones. *Eur J Pharmacol* 23:153-161, 1973
99. Lundy PM, Gowdey CW, Colhoun EH: The actions of ketamine on vascular smooth muscle. *Arch Int Pharmacodyn Ther* 220:213-230, 1976
100. Salt PJ, Barnes PK, Beswick FJ: Inhibition of neuronal and extraneuronal uptake of noradrenaline by ketamine in the isolated perfused rat heart. *Br J Anaesth* 51:835-838, 1979
101. Diaz FA, Bianco A, Bello N, et al: Effects of ketamine on canine cardiovascular function. *Br J Anaesth* 48:941-946, 1976
102. Liao JC, Koehntop DE, Buckley JJ: Dual effect of ketamine on the peripheral vasculature. *ANESTHESIOLOGY* 51:S116, 1979
103. Gooding JM, Dimick AR, Tavakoli M: A physiologic analysis of cardiopulmonary responses to ketamine anesthesia in non-cardiac patients. *Anesth Analg (Cleve)* 56:813-816, 1977
104. Folts JD, Afonso S, Rowe GG: Systemic and coronary hemodynamic effects of ketamine in intact anesthetized and unanesthetized dogs. *Br J Anaesth* 47:686-693, 1975
105. Kaukinen S: The combined effects of antihypertensive drugs and anesthetics (halothane and ketamine) on the isolated heart. *Acta Anaesth Scand* 22:649-657, 1978
106. Smith G, Thorburn J, Vance JP, et al: The effects of ketamine on the canine coronary circulation. *Anaesthesia* 34:555-561, 1979
107. Takahashi K, Shima T, Koga Y, et al: The effects of ketamine on the pulmonary hemodynamics in dogs. *Jpn J Anaesth* 20:842-846, 1971
108. Tarnow J, Hess W, Schmidt D, et al: Narkoseeinleitung bei Patienten mit koronarer Herzkrankheit: Flunitrazepam, diazepam, ketamin, fentanyl. *Anaesthesist* 28:9-11, 1979
109. Wong DHW, Jenkins LC: The cardiovascular effects of ketamine in hypotensive states. *Can Anaesth Soc J* 22:339-348, 1975
110. Longnecker DE, Sturgill BC: Influence of anesthetic agents on survival following hemorrhage. *ANESTHESIOLOGY* 45:516-521, 1976
111. Weiskopf RB, Townsley MI, Riordon KK, et al: Comparison of cardiopulmonary responses to graded hemorrhage during enflurane, halothane, isoflurane and ketamine anesthesia. *Anesth Analg (Cleve)* (in press)
112. Waxman K, Shoemaker WC, Lippmann M: Cardiovascular effects of anesthetic induction with ketamine. *Anesth Analg (Cleve)* 59:355-358, 1980
113. Stanley TH: Blood pressure and pulse rate responses to ketamine during general anesthesia. *ANESTHESIOLOGY* 39:648-649, 1973
114. Dohson MB: Anaesthesia with ketamine and thiopentone for short surgical procedures. *Anaesthesia* 33:268-270, 1978
115. Zsigmond EK, Kothary SP, Martinez OA, et al: Diazepam for prevention of the rise in plasma catecholamines caused by ketamine. *Clin Pharmacol Ther* 15:223-224, 1974
116. Jackson APF, Dhadphale PR, Callaghan ML: Haemodynamic studies during induction of anaesthesia for open-heart surgery using diazepam and ketamine. *Br J Anaesth* 50:375-377, 1978
117. Kumar SM, Kothary SP, Zsigmond EK, et al: Plasma free nor-epinephrine and epinephrine concentrations following diazepam-ketamine induction in patients undergoing cardiac surgery. *Acta Anaesthesiol Scand* 22:593-600, 1978
118. Lilburn JK, Moore J, Dundee JW: Attempts to attenuate the cardiostimulatory effects of ketamine. *Anaesthesia* 32:449-505, 1978
119. Tarnow J, Hess W: Flunitrazepam-Vorbehandlung Zur Ver-

- meidung Kardiovaskularer nebenwirkungen von ketamin. *Anaesthesist* 28:468-473, 1979
120. Shapiro HM, Wyte SR, Harris AB: Ketamine anaesthesia in patients with intracranial pathology. *Br J Anaesth* 44:1200-1204, 1972
 121. Takeshita H, Okuda Y, Sari A: The effects of ketamine on cerebral circulation and metabolism in man. *ANESTHESIOLOGY* 36:69-75, 1972
 122. Rapkin RH: Ketamine in neuroradiology. *Lancet* 1:594-595, 1971
 123. Evans J, Rosen M, Weeks RD, et al: Ketamine in neurosurgical procedures. Letter to editor. *Lancet* 1:40-41, 1971
 124. Lockhart CH, Jenkins JJ: Ketamine-induced apnea in patients with increased intracranial pressure. *ANESTHESIOLOGY* 37:92-93, 1972
 125. Dawson B, Michenfelder JD, Theye RA: Effects of ketamine on canine cerebral blood flow and metabolism: Modification by prior administration of thiopental. *Anesth Analg (Cleve)* 50:443-447, 1971
 126. Thorsen T, Gran L: Ketamine/diazepam infusion anaesthesia with special attention to the effect on cerebrospinal fluid pressure and arterial blood pressure. *Acta Anaesth Scand* 24:1-4, 1980
 127. Zsigmond EK, Matsuki A, Kothary SP, et al: Arterial hypoxemia caused by intravenous ketamine. *Anesth Analg (Cleve)* 55:311-314, 1976
 128. Rust M, Landauer B, Kolb E: Stellenwert von ketamin in der notfallsituation. *Anaesthesist* 27:205-212, 1978
 129. Maduska AL, Hajghassemali M: Arterial blood gases in mothers and infants during ketamine anesthesia for surgical delivery. *Anesth Analg (Cleve)* 57:121-123, 1978
 130. Soliman MG, Brinale GF, Kuster G: Response to hypercapnia under ketamine anaesthesia. *Can Anaesth Soc J* 22:486-494, 1975
 131. Lumb PD, Silvay G, Weinreich AI, et al: A comparison of the effects of continuous ketamine infusion and halothane on oxygenation during one-lung anesthesia in dogs. *Can Anaesth Soc J* 26:394-401, 1979
 132. Corssen G, Gutierrez J, Reves JG, et al: Ketamine in the anesthetic management of asthmatic patients. *Anesth Analg (Cleve)* 51:588-596, 1972
 133. Huber FC, Reves JG, Gutierrez J, et al: Ketamine: its effect on airway resistance in man. *South Med J* 65:1176-1180, 1972
 134. Lundy PM, Gowdy CW, Colhoun EH: Tracheal smooth muscle relaxant effect of ketamine. *Br J Anaesth* 46:333-336, 1974
 135. Wanna HT, Gergis SD: Procaine, lidocaine, and ketamine inhibit histamine-induced contracture of guinea pig tracheal muscle *in vitro*. *Anesth Analg (Cleve)* 57:25-27, 1978
 136. Hirshman CA, Downes H, Farbood A, et al: Ketamine block of bronchospasm in experimental canine asthma. *Br J Anaesth* 51:713-718, 1979
 137. Lanning CF, Harmel MH: Ketamine anesthesia. *Annu Rev Med* 26:137-141, 1975
 138. Taylor PA, Towey RM: Depression of laryngeal reflexes during ketamine anesthesia. *Br Med J* 2:688-689, 1971
 139. Penrose BH: Aspiration pneumonia following ketamine induction for a general anesthetic. *Anesth Analg (Cleve)* 51:41, 1972
 140. Radney PA, Badola RP: Generalized extensor spasm in infants following ketamine anesthesia. *ANESTHESIOLOGY* 39:459-460, 1973
 141. Zsigmond EK: Malignant hyperthermia with subsequent uneventful general anesthesia. *Anesth Analg (Cleve)* 50:1111-1112, 1971
 142. Wadhwa RK, Tantisiria B: Parotidectomy in a patient with a family history of malignant hyperthermia. *ANESTHESIOLOGY* 40:191-194, 1974
 143. Wilson A: Ketamine and muscle relaxants. *Br J Anaesth* 45:115-116, 1973
 144. Amaki Y, Nagashima H, Radnay PA, et al: Ketamine interaction with neuromuscular blocking agents in the phrenic nerve-hemidiaphragm preparation of the rat. *Anesth Analg (Cleve)* 57:238-243, 1978
 145. Marwaha J: Some mechanisms underlying actions of ketamine on electromechanical coupling in skeletal muscle. *J Neurosci Res* 5:43-50, 1980
 146. Cronnelly R, Dretchen KL, Sokoll MD, et al: Ketamine myoneural activity and interaction with neuromuscular blocking agents. *Eur J Pharmacol* 22:17-22, 1973
 147. Johnston RR, Miller RD, Way WL: The interaction of ketamine with *d*-tubocurarine, pancuronium, and succinylcholine in man. *Anesth Analg (Cleve)* 53:496-501, 1974
 148. Galloon S: Ketamine for dilation and curettage. *Can Anaesth Soc J* 18:600-613, 1971
 149. Jawalekar KS, Jawalekar SR, Mathur VP: Effect of ketamine on isolated murine myometrial activity. *Anesth Analg (Cleve)* 51:685-688, 1972
 150. Galloon S: Ketamine and the pregnant uterus. *Can Anaesth Soc J* 20:141-145, 1973
 151. Nishijima M: Ketamine in obstetric anesthesia: special reference to placental transfer and its concentration in plasma. *Acta Obstet Gynaecol Jpn* 19:80-93, 1972
 152. Dick W, Borst R, Fodor H, et al: Ketamine in obstetrical anesthesia: clinical and experimental results. *J Perinat Med* 1:252-262, 1973
 153. Peltz B, Sinclair DM: Induction agents for cesarean section: a comparison of thiopentone and ketamine. *Anaesthesia* 28:37-42, 1973
 154. Galloon S: Ketamine for obstetric delivery. *ANESTHESIOLOGY* 44:522-524, 1976
 155. Oats JN, Vasey OP, Waldron BA: Effects of ketamine on the pregnant uterus. *Br J Anaesth* 51:1163-1166, 1979
 156. Marx GF, Hwang HS, Chandra P: Postpartum uterine pressures with different doses of ketamine. *ANESTHESIOLOGY* 50:163-166, 1979
 157. Rizk SF: Ketamine is safe in acute intermittent porphyria. *ANESTHESIOLOGY* 51:184, 1979
 158. Kostrzewski E, Gregor A: Ketamine in acute intermittent porphyria—dangerous or safe? *ANESTHESIOLOGY* 49:376-377, 1978
 159. Kaniaris P, Lekakis D, Kykoniatis M, et al: Serum free fatty acid and blood sugar levels in children under halothane, thiopentone, and ketamine anaesthesia. *Can Anaesth Soc J* 22:509-518, 1975
 160. Matsuki A, Shiga T, Sanuki K, et al: Reduced triiodothyronine levels during and following ketamine-N₂O anesthesia in man. *JPN J Anaesth* 25:373-377, 1976
 161. Lin MT, Chen CF, Pang IH: Effect of ketamine on thermoregulation in rats. *Can J Physiol Pharmacol* 56:963-967, 1978
 162. Tanaka K, Pettinger WA: Renin release and ketamine-induced cardiovascular stimulation in the rat. *J Pharmacol Exp Ther* 188:229-233, 1974
 163. Kaukinen S: Effects of antihypertensive medication on the cardiovascular response to ketamine in rats. *Acta Anaesthesiol Scand* 22:437-446, 1978
 164. Miller ED, Gianfagna W, Ackerly JA, et al: Converting-enzyme activity and pressor responses to angiotensin I and II in the rat awake and during anesthesia. *ANESTHESIOLOGY* 50:88-92, 1979
 165. Fahringer EE, Foley EL, Redgate ES: Pituitary adrenal response to ketamine and the inhibition of the response by catecholaminergic blockade. *Neuroendocrinology* 14:151-164, 1974
 166. Clarke RSJ, Bali IM, Issac M, et al: Plasma cortisol and blood sugar following minor surgery under intravenous anaesthetics. *Anaesthesia* 29:545-550, 1974
 167. Takki S, Nikki P, Jaattela A, et al: Ketamine and plasma catecholamines. *Br J Anaesth* 44:1318-1322, 1972
 168. Oyama T, Matsumoto F, Kudo T: Effects of ketamine on adrenocortical function in man. *Anesth Analg (Cleve)* 49:697-700, 1970
 169. Nestico G, Pisanti N, Rotiroti D, et al: Effects of althesin and ketamine on resting and stress stimulated adrenocortical activity in rats. *Br J Anaesth* 50:891-897, 1978
 170. Adams JD, Baillie TA, Trevor AJ, et al: Studies on the biotransformation of ketamine—identification of metabolites pro-

- duced *in vitro* from rat liver microsomal preparations. Biomed Mass Spec (in press)
171. Chang T, Glazko AJ: A gas chromatographic assay for ketamine in human plasma. *ANESTHESIOLOGY* 36:401-404, 1972
172. Wieber J, Gugler R, Hengstmann JH, et al: Pharmacokinetics of ketamine in man. *Anaesthesist* 24:260-263, 1975
173. Chang T, Savory A, Albin M, et al: Metabolic disposition of tritium-labelled ketamine in normal human subjects. *Metabolic Clin Res* 18:597, 1970
174. Cohen ML, Chan SL, Bhargava HN, et al: Inhibition of mammalian brain acetylcholinesterase by ketamine. *Biochem Pharmacol* 23:1647-1652, 1974
175. White PF, Johnston RR, Pudwill CR: Interaction of ketamine and halothane in rats. *ANESTHESIOLOGY* 42:179-186, 1975
176. Cohen ML, Chan SL, Way WL, et al: Distribution in the brain and metabolism of ketamine in the rat after intravenous administration. *ANESTHESIOLOGY* 39:370-376, 1973
177. White PF, Marietta MP, Pudwill CR, et al: Effects of halothane anesthesia on the biodisposition of ketamine in rats. *J Pharmacol Exp Ther* 196:545-555, 1976
178. Marietta MP, White PF, Pudwill CR, et al: Biodisposition of ketamine in the rat: self-induction of metabolism. *J Pharmacol Exp Ther* 196:536-544, 1976
179. Letaget J, Bouletreau P, Gilles YD, et al: Ketamine et insuffisance renale. *Anesth Analg (Paris)* 29:261-264, 1972
180. Zsigmond EK, Domino EF: Ketamine—clinical pharmacology, pharmacokinetics, and current clinical uses. *Anesth Rev* 7:13-33, 1980
181. Lo JN, Cumming JF: Interaction between sedative premedicants and ketamine in man and in isolated perfused rat livers. *ANESTHESIOLOGY* 43:307-312, 1975
182. Wyant GM: Intramuscular ketalar (CI-581) in paediatric anaesthesia. *Can Anaesth Soc J* 18:72-83, 1971
183. Wessels JV, Allen GW, Slogoff S: The effect of nitrous oxide on ketamine anesthesia. *ANESTHESIOLOGY* 39:382-386, 1973
184. Marietta MP, Vore ME, Way WL, et al: Characterization of ketamine induction of hepatic microsomal drug metabolism. *Biochem Pharmacol* 26:2451-2453, 1977
185. Cronin MM, Bousfield JD, Hewitt GB, et al: Ketamine anesthesia for radiotherapy in small children. *Anesthesia* 27:135-142, 1972
186. Bennett JA, Bullimore JA: The use of ketamine hydrochloride anaesthesia for radiotherapy in young children. *Br J Anaesth* 45:197-201, 1973
187. Demling RH, Ellerbee S, Jarrett F: Ketamine anesthesia for tangential excision of burn eschar: a burn unit procedure. *J Trauma* 18:269-270, 1978
188. Cumming JF: The development of an acute tolerance to ketamine. *Anesth Analg (Cleve)* 55:788-791, 1976
189. Meliska CJ, Trevor AJ: Differential effects of ketamine on scheduled-controlled responding and motility. *Pharmacol Biochem Behav* 8:679-683, 1978
190. Moreton JE, Meisch RA, Stark K, et al: Ketamine self-administration by the rhesus monkey. *J Pharmacol Exp Ther* 203:303-309, 1977
191. Reier CE: Ketamine-dissociative agent or hallucinogen? *N Engl J Med* 284:791-792, 1971
192. Siegel RK: Phencyclidine and ketamine intoxication. *Natl Inst Drug Abuse Research* 21:119-147, 1978
193. Ketamine abuse. *FDA Drug Bull* 9:24, 1979
194. Shulgin AT: Stereospecific requirements for hallucinogenesis. *J Pharmacol* 25:271-272, 1973
195. Segal DS: Behavioral characterization of d- and l-amphetamine: neurochemical implications. *Science* 190:475-476, 1975
196. Portoghese PS: Stereochemical factors and receptors interactions associated with narcotic analgesics. *J Pharm Sci* 55:865-887, 1966
197. Haley TJ, Gidley JT: Pharmacological comparison of R(+), S(-) and racemic thiopentone in mice. *Eur J Pharmacol* 36:211-214, 1976
198. Marietta MP, Way WL, Castagnoli N, et al: On the pharmacology of the ketamine enantiomorphs in the rat. *J Pharmacol Exp Ther* 202:157-165, 1977
199. Ryder S, Way WL, Trevor AJ: Comparative pharmacology of the optical isomers of ketamine in mice. *Eur J of Pharmacol* 49:15-23, 1978
200. Meliska CJ, Greenberg AJ, Trevor AJ: The effects of ketamine enantiomers on schedule-controlled behavior in the rat. *J Pharmacol Exp Ther* 212:198-202, 1980
201. Roberts FW: A new intramuscular anesthetic for small children. *Anaesthesia* 22:23-28, 1967
202. Corssen G, Dget S: Dissociative anesthesia for the severely burned child. *Anesth Analg (Cleve)* 50:95-102, 1971
203. Lorhan PH, Lippmann M: A clinical appraisal of the use of ketamine hydrochloride in the aged. *Anesth Analg (Cleve)* 50:448-451, 1971
204. Szappanyos G, Gemperle M, Rifat K: Selective indications for ketamine anaesthesia. *Proc R Soc Med* 64:1156-1159, 1971
205. Barson P, Arens JF: Ketamine as an induction anesthetic for poor-risk patients. *South Med J* 67:1398-1402, 1974
206. Vaughan RW, Stephen CR: Abdominal and thoracic surgery in adults with ketamine, nitrous oxide, and d-tubocurarine. *Anesth Analg (Cleve)* 53:271-280, 1974
207. Peter K, van Ackern K, Frey B, et al: Die wirkung verschiedener narkotika auf herz und kreislauf bei der narkoseeinleitung im frunhen hamorrhagischen schock. *Z Prakt Anaesth* 7:263-270, 1972
208. Chasapakis G, Kekis N, Sakalis C, et al: Use of ketamine and pancuronium for anaesthesia for patients in hemorrhagic shock. *Anesth Analg (Cleve)* 52:282-287, 1973
209. Bond AC, Davies CK: Ketamine and pancuronium for the shocked patient. *Anaesthesia* 29:59-62, 1974
210. Spieckermann PG, Braun U, Hellberg K, et al: Überlebens- und wiederbele-bungszeit des herzens während ketamine-, barbiturat- und halothan-narkose. *Z Prakt Anaesth* 5:365-372, 1970
211. Betts GK, Parkin CE: Use of ketamine in an asthmatic child: a case report. *Anesth Analg (Cleve)* 50:420-421, 1971
212. Fischer MM: Ketamine hydrochloride in severe bronchospasm. *Anesthesia* 32:771-772, 1977
213. Chodoff P, Stella JC: Use of CI-581, a phencyclidine derivative for obstetric anesthesia. *Anesth Analg (Cleve)* 45:527-530, 1966
214. Akamatsu TJ, Boreca JJ, Rehmet R: Experiences with the use of ketamine for parturition. 1. Primary anesthetic for vaginal delivery. *Anesth Analg (Cleve)* 53:284-287, 1974
215. Janeczko GF, El-Etr AA, Younes, S: Low-dose ketamine anesthesia for obstetrical delivery. *Anesth Analg (Cleve)* 53:828-831, 1974
216. Ellingson A, Haram K, Sagen N: Ketamine and diazepam as anesthesia for forceps delivery. A comparative study. *Acta Anaesth Scan* 21:37-40, 1977
217. Krantz ML: Ketamine in obstetrics—comparison with methoxyflurane. *Anesth Analg (Cleve)* 53:890-893, 1974
218. Meer FM, Downing JW, Coleman AJ: An intravenous method of anesthesia for caesarean section. Part II. Ketamine. *Br J Anaesth* 45:191-196, 1973
219. Downing JW, Mahomed MC, Jeal DE, et al: Anaesthesia for caesarean section with ketamine. *Anaesthesia* 31:883-892, 1976
220. Bunodiére M, Green M, Bunodieve N, et al: Le chlorhydrate de ketamine pour l' anesthésie en obstétrique. *Anesth Analg (Paris)* 32:187-197, 1975
221. Rucci FS, Caroli G: Ketamine and eclampsia. *Br J Anaesth* 46:546, 1974
222. Levinson G, Shnider SM, Gildea JE, et al: Maternal and foetal cardiovascular and acid-base changes during ketamine anaesthesia in pregnant ewes. *Br J Anaesth* 45:1111-1115, 1973
223. Marx GF, Cabe CM, Kim YI, et al: Neonatal blood pressures. *Anaesthesist* 25:318-322, 1976
224. Hodgkinson K, Marx GF, Kim SS, et al: Neonatal neurobehavioral tests following vaginal delivery under ketamine, thiopental, and extradural anesthesia. *Anesth Analg (Cleve)* 56:548-553, 1977

225. Carrel R: Ketamine: a general anesthetic for unmanageable ambulatory patients. *ASDC J Dent Child* 40:288-292, 1973
226. Cohenour K, Gamble JW, Metzgar MT, et al: A composite general anesthesia for pediatric outpatients. *J Oral Surgery* 36:594-598, 1978
227. Jastak JT, Goretta C: Ketamine as a continuous-drip anesthetic for outpatients. *Anesth Analg (Cleve)* 52:341-344, 1973
228. Saarnivaara L: Comparison of thiopentone, althesin, and ketamine in anaesthesia for otolaryngological surgery in children. *Br J Anaesth* 49:363-369, 1977
229. Barson PK, Scott ML, Lawson NW, et al: Ketamine for bronchoscopy of children. *South Med J* 67:1403-1404, 1974
230. ApIvor D: Ketamine in paediatric ophthalmological surgery. An evaluation of its efficacy and postoperative effects. *Anaesthesia* 28:501-508, 1973
231. Yoshikawa K, Murai Y: The effect of ketamine on intraocular pressure in children. *Anesth Analg (Cleve)* 50:199-202, 1971
232. Adams A: Ketamine in paediatric ophthalmic practice. *Anaesthesia* 28:212-213, 1973
233. Peuler M, Glass DD, Arens JF: Ketamine and intraocular pressure. *ANESTHESIOLOGY* 43:575-578, 1975
234. Ausinsch B, Rayburn RL, Munson ES, et al: Ketamine and intraocular pressure in children. *Anesth Analg (Cleve)* 55:773-775, 1976
235. Saint-Maurice C, Laguenie G, Couturier C, et al: Rectal ketamine in paediatric anaesthesia. *Br J Anaesth* 51:573-574, 1979
236. Figallo EM, McKenzie R, Tantisira B, et al: Anaesthesia for dilation, evacuation, and curettage in outpatients. A comparison of subanaesthetic doses of ketamine and sodium methohexitone-nitrous oxide anaesthesia. *Can Anaesth Soc J* 24:110-117, 1977
237. El-Naggar M, Letcher J, Middleton E, et al: Administration of ketamine or Innovar® by the microdrip technique: a double-blind study. *Anesth Analg (Cleve)* 56:279-282, 1977
238. Ayim EN: Experience with Ketalar®. *E Afr Med J* 50:436-443, 1973
239. Thompson GE, Moore DC: Ketamine, diazepam, and Innovar®: a computerized comparative study. *Anesth Analg (Cleve)* 50:458-463, 1971
240. Beekhuis GJ, Kahn DL: Anesthesia for facial cosmetic surgery. Low dosage ketamine-diazepam anesthesia. *Laryngoscope* 88:1709-1712, 1978
241. Dillon JB: Rational use of ketamine as an anaesthetic. *Proc R Soc Med* 64:1153-1156, 1971
242. Coppel DL, Dundee JW: Ketamine anesthesia for cardiac catheterization. *Anaesthesia* 27:25-31, 1972
243. Faithful NS, Haider R: Ketamine for cardiac catheterization. An evaluation of its use in children. *Anaesthesia* 26:318-323, 1971
244. Hatano S, Keane DM, Boggs RE, et al: Diazepam-ketamine anaesthesia for open heart surgery—a micro-mini drip administration technique. *Can Anaesth Soc J* 23:648-656, 1976
245. Reves JG, Lell, WA, McCracken, LE, et al: Comparison of morphine and ketamine. Anesthetic techniques for coronary surgery: a randomized study. *South Med J* 71:33-36, 1978
246. Dhadphale PR, Jackson APF, Alseri S: Comparison of anesthesia with diazepam and ketamine vs. morphine in patients undergoing heart-valve replacement. *ANESTHESIOLOGY* 51:200-203, 1979
247. Spotoft H, Korshin JD, Sorensen MB, et al: The cardiovascular effects of ketamine used for induction of anaesthesia in patients with valvular heart disease. *Can Anaesth Soc J* 26:463-467, 1979
248. Silvay G, Weinrich A, Lumb P, et al: Continuous ketamine for one-lung anesthesia as an alternative to halothane. *Excerpta Med Int Cong Ser* 452:140-141, 1978
249. Ito Y, Ichihyanagi K: Post-operative pain relief with ketamine infusion. *Anaesthesia* 29:222-229, 1974
250. Clausen L, Sinclair DM, Van Hasselt CH: Intravenous ketamine for postoperative analgesia. *S Afr Med J* 49:1437-1440, 1975
251. Hatano S, Nishiwada M, Matsumura M: Ketamine—diazepam anesthesia for abdominal surgery. *Anaesthetist* 27:172-182, 1978
252. Kamm GD, Bewes PC: Ketamine anaesthesia by continuous intravenous drip. *Trop Doct* 8:68-72, 1978
253. Lilburn JK, Dundee JW, Moore J: Ketamine infusions—observations on technique dosage and cardiovascular effects. *Anaesthesia* 33:315-321, 1978
254. Wilson RO, Richey JV, Forestner JE, et al: Cardiovascular effects of drip ketamine. *ANESTHESIOLOGY* 51:S35, 1979
255. Pandit SK, Kothary SP, Kumar SM: Low-dose intravenous infusion technique with ketamine. *Anaesthesia* 35:698-675, 1980